The epidemiology of herpes simplex virus type 2 in sub-Saharan Africa: systematic review, meta-analyses, and meta-regressions

Manale Harfouche, Farah M. Abu-Hijleh, Charlotte James, Katharine J. Looker, Laith J. Abu-Raddad
doi: https://doi.org/10.1101/2021.01.25.21250443

Abstract

Background Herpes simplex virus type 2 (HSV-2) infection is a prevalent sexually transmitted infection with a sizable disease burden that is highest in sub-Saharan Africa. This study aimed to characterize HSV-2 epidemiology in this region.

Methods Cochrane and PRISMA guidelines were followed to systematically review, synthesize, and report HSV-2 related findings. Meta-analyses and meta-regressions were conducted.

Findings From 218 relevant publications, 451 overall outcome measures and 869 stratified measures were extracted. Pooled incidence rates ranged between 2.4-19.4 per 100 person-years across populations. Pooled seroprevalence was lowest at 37.3% (95% confidence interval (CI): 34.9-39.7%) in general populations and high in female sex workers and HIV positive individuals at 62.5% (95% CI: 54.8-70.0%) and 71.3% (95% CI: 66.5-75.9%), respectively. In general populations, pooled seroprevalence increased steadily with age. Compared to women, men had a lower seroprevalence with an adjusted risk ratio (ARR) of 0.61 (95% CI: 0.56-0.67).

Seroprevalence decreased in recent decades with an ARR of 0.98 (95% CI: 0.97-0.99) per year. Seroprevalence was highest in Eastern and Southern Africa. Pooled HSV-2 proportion in genital ulcer disease was 50.7% (95% CI: 44.7-56.8%) and in genital herpes it was 97.3% (95% CI: 84.4-100%).

Interpretation Seroprevalence is declining by 2% per year, but a third of the population is infected. Age and geography play profound roles in HSV-2 epidemiology. Temporal declines and geographic distribution of HSV-2 seroprevalence mirror that of HIV prevalence, suggesting sexual risk behavior has been declining for three decades. HSV-2 is the etiological cause of half of GUD and nearly all genital herpes cases.

Funding This work was supported by pilot funding from the Biomedical Research Program at Weill Cornell Medicine in Qatar and by the Qatar National Research Fund [NPRP 9-040-3-008].

Introduction

Herpes simplex virus type 2 (HSV-2) infection is a highly prevalent sexually transmitted infection (STI) worldwide.(1) It is a leading cause of genital ulcer disease (GUD) and genital herpes, manifesting in the form of painful, recurrent, and frequent genital lesions.(2–8) Its vertical transmission from mother-to-child can lead to neonatal herpes, a severe and sometimes fatal outcome in newborns.(3, 9) HSV-2 is linked to a 3-fold increase in sexual transmission and acquisition of HIV,(10–12) implying a potential epidemiological synergy between the two viruses.(11, 13, 14)

HSV-2 is typically asymptomatic in most of those who acquire it.(3) This trait coupled with HSV-2’s chronic and reactivating nature, as well as its subclinical shedding,(15, 16) increases its rate of transmission and leads to high antibody prevalence (seroprevalence) among general and higher-risk populations alike.(11, 17, 18) Since HSV-2 is more transmissible than HIV and produces long-lasting antibodies, it has been used as an objective biological marker of sexual risk behavior and risk of HIV infection.(19–23) Analyses using empirical data and mathematical modeling supported the utility of using HSV-2 seroprevalence to predict HIV epidemic potential.(19, 20, 24)

Inadequate understating of HSV-2 epidemiology and its considerable consequences on sexual and reproductive health and the HIV epidemic,(11, 13) calls for urgent preventive and control measures to tackle it. The World Health Organization (WHO) outlined a “Global Health Sector Strategy on STIs”(25) that sets goals to eliminate STIs as a main public health concern by 2030 through integration of preventive and control measures. Consequently, WHO, along with their global partners, are spearheading efforts to develop an HSV vaccine as an urgent priority.(26, 27)

To inform these efforts, we conducted a systematic review to characterize HSV-2 infection levels and trends in sub-Saharan Africa (SSA), the hub of the HIV epidemic.(28, 29) We estimated pooled means for each outcome measure (incidence rate, seroprevalence, proportion of HSV-2 in GUD, and proportion of HSV-2 in genital herpes) across populations and subpopulations. We also conducted meta-regression analyses to assess temporal trends and identify predictors of high seroprevalence and between-study heterogeneity.

Methodology

Data sources and search strategy

This systematic review was guided by the Cochrane Collaboration Handbook(30) and was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines(31) which can be found in Table S1. The review was informed by the methodology applied recently in a series of systematic reviews for HSV-1 infection.(32–36)

All available publications were systematically reviewed up to August 23, 2020. The search was conducted in PubMed and Embase databases, using search strategies with exploded MeSH/Emtree terms, broad search criteria, and no language or year restrictions to widen the scope and include all subheadings (Table S2). The definition of Africa included 45 countries, as defined by the WHO for the African Region,(37) covering countries of sub-Saharan Africa. The list of countries and their subregional stratification is in Box S1.

Study selection and eligibility criteria

Search results were imported into the reference manager Endnote (Thomson Reuters, USA), whereby duplicate publications were identified and removed. The remaining records were screened for relevance based on titles and abstracts, followed by full text screening of relevant and potentially relevant records. Additional bibliography screening was performed on both reviews and the relevant articles to identify any missing publications.

Inclusion criteria were met if publications reported primary data on any of the following four outcomes: 1) HSV-2 incidence rate, 2) HSV-2 seroprevalence, 3) proportion of HSV-2 detection in GUD, and 4) proportion of HSV-2 detection in genital herpes. A sample size of ≥10 was required for inclusion for all outcome measures. Exclusion criteria encompassed case reports, series, commentaries, reviews, and qualitative studies. In this review, “publication” refers to a document reporting any outcome measure, whilst a “study” refers to details of a specific outcome measure. Special care was given to ensure that overlapping studies were only included once and not in duplicate.

Data extraction and synthesis

Data extraction and double extraction were performed by MH and FA independently. A list of extracted variables is in Box S2.

Overall outcome measures and their stratified measures were extracted, provided the stratification agreed with a pre-set stratification hierarchy and the subsample in each stratum was ≥10. The pre-set stratification hierarchy sequence for incidence and seroprevalence measures was as follows: population type (see Box S3 for definition), sex, and age. As for proportion of HSV-2 detection in GUD and genital herpes, the sequence was: genital herpes episode status (primary versus recurrent episode), sex, age, and study site (hospital versus outpatient clinic).

Measures reporting any HSV-2 outcome among children <15 years old were only reported, and not included in the analyses.

Quality assessment

Relevant studies were subjected to a pre-quality assessment to evaluate the validity of the assays used, given their limitations.(38, 39) This assessment was done with the help of an expert from the University of Washington, Professor Rhoda Ashley-Morrow. Only studies with valid, sensitive, and specific assays were included in the review. These studies were then evaluated using the Cochrane approach for risk of bias (ROB) assessment.(30) Study’s precision was classified into low versus high based on the study sample size (<100 versus ≥100).(40) Studies were classified into low versus high ROB using two quality domains: sampling method (probability versus non-probability based sampling) and response rate (≥80% versus <80% or unclear). Effect of ROB on study outcome was investigated through meta-regression as noted below.

Meta-analyses

Pooled mean estimates for all four outcomes were calculated across all strata using meta-analyses, provided each stratum had ≥3 measures.

Only studies reporting incidence rate by person-time were included in the meta-analyses. Log transformed incidence rates were used to calculate pooled estimates using the inverse variance method in the metarate function.(41, 42)

HSV-2 seroprevalence measures and proportion of HSV-2 detection in GUD and in genital herpes were each pooled using the DerSimonian-Laird random-effects model,(41) applying the Freeman-Tukey double arcsine transformation to stabilize the variance,(43) and factoring knowledge of the applicability of this transformation.(44)

Existence of heterogeneity in effect size was assessed using Cochran’s Q statistic.(41, 45) Magnitude of between-study variation attributed to true difference in effect size, as opposed to chance, was measured using I2.(41, 45) Distribution of true measures around the pooled mean was described using the prediction interval.

Meta-analyses were conducted in R version 3.4.1(46) using the meta package.(42)

Meta-regressions

Univariable and multivariable random-effects meta-regression analyses were conducted using log transformed seroprevalence measures to examine factors and predictors potentially associated with increased HSV-2 seroprevalence, as well as sources of between-study heterogeneity. Pre-set variables included in these analyses are listed in Box S4.

Factors included in the multivariable models had to have a p-value<0.1 in the univariable model. Strength of evidence for an association was deemed significant for factors with a p-value<0.05 in the multivariable models.

Meta-regressions were conducted in Stata/SE version 13(47) using the metareg package.(48)

Role of the funding source

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the article. The corresponding author had full access to all the data in the study and had the final responsibility for the decision to submit for publication.

Results

Search results and scope of evidence

Figure 1 depicts the PRISMA flow chart describing the study selection process.(31) A total of 14,830 citations were captured in the initial search (2,039 from PubMed and 12,791 from Embase). After deduplication, title and abstract screening, and full text screening, relevant publications were identified. Thirteen additional publications, including country level reports, were identified through bibliography screening.(49–61)

Figure 1.
Figure 1.

Flow chart of article selection for the systematic review of HSV-2 infection in sub-Saharan Africa, per the PRISMA guidelines.(31)

In total, 218 publications met the inclusion criteria. Extracted measures encompassed 47 seroconversion rates, 48 overall (65 stratified) incidence rates, 322 overall (773 stratified) seroprevalence measures, 25 overall (31 stratified) proportions of HSV-2 detection in GUD, and 9 overall (11 stratified) proportions of HSV-2 detection in genital herpes.

Incidence overview and pooled mean estimates for HSV-2 incidence rate

Table S3 summarizes extracted seroconversion and incidence rates. Studies were either longitudinal cohorts (number of measures (n)=35; 49.2%) or randomized controlled trials (n=36; 50.7%), with a follow-up duration ranging between 6 weeks to 6 years. HSV-2 seroconversion rates (n=47) ranged between 0.0-58.0% across studies, reflecting in part the widely variable duration of follow-up.

In general populations, HSV-2 incidence rates among women (n=20) ranged between 3.6-21.7 per 100 person-years with a median of 7.5 and a pooled mean of 7.2 (95% confidence interval (CI): 5.5-9.4) per 100 person-years (Table 1). Among men (n=20), incidence rate ranged between 1.5-10.5 per 100 person-years with a median of 5.5 and a pooled mean of 4.1 (95% CI: 3.1-5.3) per 100 person-years. Higher incidence rates were found in higher risk populations. A summary of pooled mean incidence rate by population type and associated forest plots are in Table 1 and Figure S1, respectively.

View this table:
Table 1.

Pooled mean estimates for herpes simplex virus type 2 incidence rate among different populations in sub-Saharan Africa.

Prevalence overview

Tables S4, S5, S6, S7, and S8 summarize (the overall) seroprevalence measures (n=322) across the subregions of SSA. Half the studies were published after the year 2010 (n=176; 55.5%), and most were based on cross-sectional study design (n=202; 62.7%) and convenience sampling (n=233; 72.4%).

For the stratified seroprevalence measures, HSV-2 seroprevalence among general population women (n=290) ranged between 0.1-97.4% with a median of 43.1%, and among general population men (n=186) between 0.0-84.2% with a median of 27.5% (Table 2).

View this table:
Table 2.

Pooled mean estimates for herpes simplex virus type 2 seroprevalence among the different at risk populations in sub-Saharan Africa by sex.

In higher-risk populations (n=40), almost all studies were conducted among female sex workers (FSWs; n=39) with seroprevalence ranging between 4.3-99.0% with a median of 65.0% (Table 2). High seroprevalence was observed in HIV positive individuals and in individuals in HIV discordant couples, ranging between 42.0-95.2% with a median of 79.7% among women (n=20), and between 44.0-94.2% with a median of 61.4% among men (n=15).

Tables 2, 3, and S9 summarize HSV-2 seroprevalence measures for further populations and subpopulations, including by population type, country, subregion, age, sex, and year of publication.

View this table:
Table 3.

Pooled mean estimates for herpes simplex virus type 2 seroprevalence among general populations in sub-Saharan Africa.

Pooled mean estimates for HSV-2 seroprevalence

Tables 2, 3, and S9 show results of seroprevalence meta-analyses across populations and subpopulations. Pooled mean seroprevalence was lowest at 37.3% (95% CI: 34.9-39.7%) in general populations (n=507), followed by 47.4% (95% CI: 43.2-51.5%) in HIV negative populations (n=51), 57.1% (95% CI: 50.1-63.9%) in intermediate-risk populations (n=45), 61.2% (95% CI: 56.5-65.9%) in STI clinic attendees and symptomatic populations (n=72), 61.4% (95% CI: 53.4-69.1%) in higher-risk populations (n=40; mainly FSWs), and 71.3% (95% CI: 66.5-75.9%) in HIV positive individuals and in individuals in HIV discordant couples (n=42; Table 2).

Among general populations, the pooled mean seroprevalence varied across African subregions (Table 3), with the lowest being 25.0% (95% CI: 20.9-29.4%) in Western Africa (n=68), followed by 35.8% (95% CI: 31.6-40.0%) in Southern Africa (n=226), 41.9% (95% CI: 38.4-45.3%) in Eastern Africa (n=188), and 52.4% (95% CI: 40.4-64.3%) in Central Africa (n=25). Similar hierarchy was observed across subregions for women and men, with women having consistently higher pooled mean seroprevalence compared to men (Table S9).

Across age groups (Table 3), pooled mean seroprevalence increased gradually from 12.4% (95% CI: 10.6-14.3%) in those <20 years-old (n=88), followed by 34.2% (95% CI: 30.7-37.8%) in those 20-30 years-old (n=112), 57.1% (95% CI: 54.8-63.3%) in those 30-40 years-old (n=69), 64.6% (95% CI: 59.5-69.5%) in those 40-50 years-old (n=48), to then decrease slightly to 58.2% (95% CI: 50.3-65.9%) in those >50 years-old. A similar trend was observed across age groups for each of women and men, but seroprevalence grow faster with age for young women (Table S9).

Heterogeneity was evident in almost all meta-analyses (p-value<0.001), and was confirmed by the wide prediction intervals (Tables 2, 3, and S9). Most heterogeneity was attributed to true variation in seroprevalence rather than chance (I2>50%). Forest plots for meta-analyses across African subregions stratified by population type are in Figure S2.

Predictors of HSV-2 seroprevalence

Table 4 shows results of the meta-regression analyses for HSV-2 seroprevalence. Nine variables were eligible for inclusion in the multivariable model (p-value<0.1 in univariable analysis). Two multivariable models were conducted, one including year of publication as a categorical variable and one including it as a linear term.

View this table:
Table 4.

Univariable and multivariable meta-regression analyses for herpes simplex virus type 2 seroprevalence in sub-Saharan Africa.

The model including year of publication as a categorical variable explained 57.5% of seroprevalence variation and included population type, age group, sex, African subregion, country’s income, assay type, sampling method, response rate, and year of publication category (Table 4). Compared to general populations who had the lowest seroprevalence, seroprevalence was highest in HIV positive individuals and in individuals in HIV discordant couples [adjusted risk ratio (ARR) of 2.17 (95% CI: 1.78-2.65)], followed by STI clinic attendees and symptomatic populations, higher-risk populations, intermediate-risk populations, and HIV negative populations.

Compared to women, men had a 0.61-fold (95% CI: 0.56-0.67) lower seroprevalence. Seroprevalence increased rapidly with age at young age, but the increase plateaued by age 40-50 years. Seroprevalence was highest in Eastern Africa, followed by Southern Africa, Central Africa, and lowest in Western Africa. Country’s income was not associated with seroprevalence.

Studies that had a lower or unknown response rate had a higher seroprevalence. Meanwhile, assay type, study sample size, and study sampling method were not associated with seroprevalence.

Compared to those published before the year 2005, studies published in 2006-2015 [ARR of 0.85 (95% CI: 0.76-0.96)] and after 2015 [ARR of 0.80 (95% CI: 0.69-0.93)] had lower seroprevalence.

The model including year of publication as a linear term (Table 4) showed similar results and indicated declining seroprevalence with time [ARR of 0.98 (95% CI: 0.97-0.99)]. The model explained 57.5% of seroprevalence variation

Sensitivity analyses including year of data collection as a categorical variable or as a linear term (in replacement of year of publication) arrived at similar results (Table S10).

Overview and meta-analyses of HSV-2 isolation in genital ulcer disease and in genital herpes

Table S11 summarizes extracted proportions of HSV-2 detection in GUD and in genital herpes. In GUD cases (n=31), proportion of HSV-2 detection ranged between 8.3-100% with a median of 49.1% and a pooled mean proportion of 50.7% (95% CI: 44.7-56.8%) (Table 5). Among women (n=8), it ranged between 35.0-100% with a median of 49.5% and a pooled proportion of 59.0% (95% CI: 44.7-72.6%), and among men (n=13), it ranged between 8.3-72.2% with a median of 49.1% and a pooled proportion of 47.3% (95% CI: 37.2-57.5%).

View this table:
Table 5.

Pooled proportions of herpes virus type 2 (HSV-2) virus isolation in clinically-diagnosed GUD and in clinically-diagnosed genital herpes in Africa.

In genital herpes cases (n=11), proportion of HSV-2 detection ranged between 53.0-100% with a median of 100% and a pooled mean proportion of 97.3% (95% CI: 84.4-100%) (Table 5). No study distinguished between primary and recurrent genital herpes episodes.

These meta-analyses showed evidence of heterogeneity (p-value<0.001, I²>50%, and wide prediction intervals). Forest plots are in Figure S3.

Quality assessment

Quality assessment of diagnostic methods excluded 51 publications due to potential issues in the implemented diagnostic assays. Quality assessment of included seroprevalence measures is summarized in Table S12. Briefly, 288 studies (89.4%) had high precision, 88 studies (27.3%) and 85 studies (26.4%) had low ROB in the sampling method and in the response rate domains, respectively. Twenty-three studies (7.1%) had high ROB in both quality domains.

Discussion

This systematic review presented a detailed assessment of HSV-2 epidemiology in sub-Saharan Africa. Strikingly, the results demonstrate that HSV-2 seroprevalence has been declining by about 2% per year over the last three decades (Table 4). This decline is in line with the observed declines in HIV epidemics in SSA during the same timeframe.(62) Drivers of the decline in HIV prevalence have been subject to debate, with various mechanisms posited including natural epidemic dynamics,(63) increased HIV-associated mortality,(64, 65) impact of interventions,(65) heterogeneity in host susceptibility to HIV infection,(66, 67) and reductions in sexual risk behavior.(65, 68–71) Considering that HSV-2 seroprevalence has been shown to provide an objective proxy biomarker of population-level sexual risk behavior,(19–24) our finding of rapidly declining HSV-2 seroprevalence suggests that sexual risk behavior has been declining, and that this decline has reduced the transmission of both HIV and HSV-2 infections. With evidence of HSV-2 infection increasing risk of HIV acquisition and transmission,(10–13) it remains to be seen whether the declining HSV-2 incidence may have also contributed to the declines seen in HIV incidence in SSA.

Despite declining HSV-2 transmission in SSA, incidence rate is still high (Table 1), and much higher than that found elsewhere in the world.(1) For instance, the incidence rate in the United States (<1 per 100 person-years)(72) is an order of magnitude lower than that in SSA. The results further demonstrate that age plays a profound effect in HSV-2 epidemiology—age alone accounted for 30% of the seroprevalence variation (Table 4). HSV-2 infection in SSA is typically acquired at a young age not long after sexual debut, especially so for women, manifesting in a rapidly increasing seroprevalence with age before plateauing at high levels by ages 40-50 (Tables 1, 3, 4, and S9).

Population risk classification was also found to play an important role in HSV-2 epidemiology, accounting for 13% of seroprevalence variation (Table 4). Both incidence rate and seroprevalence were found at much higher levels in specific at-risk populations, such as female sex workers (Tables 2 and 4), with both measures displaying the “classical hierarchy” of STI exposure by sexual risk behavior, also seen with other STIs.(73, 74) Despite its prominence amongst higher risk populations, HSV-2 infection is also widely disseminated in SSA with high levels of infection even in the lower risk general population where over a quarter of men and nearly half of women are infected (Tables 2 and 4).

Although HSV-2 seroprevalence is high everywhere in SSA, there are still considerable variations by subregion. Infection levels were highest in Eastern Africa followed by Southern Africa, Central Africa, and lowest in Western Africa (Table 4). Incidentally, this pattern is also seen for HIV infection with Eastern Africa and Southern Africa being most affected and Western Africa least affected.(75, 76) This further suggests a strong link between HSV-2 and HIV epidemiologies,(24) reflecting a similar mode of transmission and hinting at a biological/epidemiological synergy.(10–14) The results further demonstrate that women are almost twice as likely to be infected as men (Table 4), reflecting a higher bio-anatomical susceptibility to the infection.(77, 78)

Another finding of this study is that HSV-2 infection is the cause of half of GUD cases in SSA (Table 5), confirming that this infection is the main cause of this disease in this part of the world where nearly 60 million individuals are estimated to be affected with HSV-related GUD.(79)

Although HSV-2 seroprevalence is declining (Table 4), it will likely remain the main cause of GUD in SSA, as other causes such as syphilis have also been declining.(80, 81) HSV-2 infection (as opposed to HSV-1 infection) was also found to account for nearly all cases of genital herpes (>97%; Table 5). This finding is presumably due to the nature of HSV-1 being widely acquired in childhood in SSA through oral transmission,(33) and distinguishes this region from other global regions where there is an increasing role for HSV-1 in genital herpes,(33–36) with some countries already observing HSV-1 as the cause of a large proportion of cases of genital herpes.(33–36)

This study had limitations, principally the unavailability of data for 15 of 45 African countries. There was also less data for Central and Western Africa than for Eastern and Southern Africa, in addition to data for seroprevalence eclipsing those of GUD and genital herpes. Despite these limitations, a large volume of data was available to sufficiently power an array of analyses. Included studies exhibited heterogeneity (Tables 2, 3, and S9); however, more than half of this heterogeneity (57%) was subsequently explained through meta-regressions (Table 4). Studies differed by assay type, sample size, sampling method, and response rate, yet none of these study characteristics appeared to affect seroprevalence with the exception of response rate where studies with lower or unknown response rate had a higher seroprevalence (Table 4). Overall, these limitations should not pose a barrier to the critical interpretation of this study’s results, or its findings.

Conclusions

In conclusion, HSV-2 seroprevalence is declining rapidly in SSA. Yet, HSV-2 incidence and seroprevalence remain at high levels, with over a third of the population being infected. Age and subregion within SSA play a critical role in HSV-2 epidemiology and explain much of the observed variation in seroprevalence. The geographical distribution of this infection was also found to be similar to that of HIV infection, and the declines in HSV-2 seroprevalence mirrored those for HIV prevalence. These findings suggest that the declines in both infections were driven by reductions in sexual risk behavior following the massive expansion of the HIV epidemic in this continent, and may suggest that some of the declines in HIV incidence could have been attributed to the declines in HSV-2 incidence. HSV-2 infection was found to be the etiological cause of half of GUD cases in this region, and virtually all cases of genital herpes. These findings demonstrate the urgent need for both prophylactic and therapeutic HSV-2 vaccines to tackle the disease burden of this infection,(82) and argue for further acceleration of ongoing efforts for vaccine development.(26, 27, 83)

Data Availability

All relevant data are available within the manuscript and its supplementary materials.

Contributors

MH and FAH conducted the systematic search, data extraction, and data analysis. MH wrote the first draft of the paper. CJ and KJL contributed to the systematic search, data extraction, and interpretation of the results. LJA conceived the study and led the data extraction and analysis and interpretation of the results. All authors contributed towards drafting and revising the manuscript.

Declaration of interests

MH, FAH, CJ, and LJA declare no competing interests. KL is currently funded by GlaxoSmithKline (GSK) for a gonorrhea vaccine modeling project.

View this table:
Table S1.

Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) checklist.(1)

View this table:
Table S2.

Data sources and search criteria for systematically reviewing HSV-2 epidemiology in sub-Saharan Africa.

Box S1.

List of the 45 countries included in our definition for sub-Saharan Africa by subregion.(2)

Figure

Box S2.

List of variables extracted from the relevant publications meeting the inclusion criteria.

Figure

Box S3.

Definitions of population type classifications.

Figure

Box S4.

Variables included in the univariable and multivariable meta-regression analyses.

Figure

View this table:
Table S3.

Studies reporting HSV-2 seroconversion rate or incidence rate in sub-Saharan Africa.

Figure S1.
Figure S1.

Forest plot presenting the outcome of the pooled mean herpes simplex virus type 2 (HSV-2) incidence rate by population type in sub-Saharan Africa.

View this table:
Table S4.

Studies reporting HSV-2 seroprevalence in Eastern Africa. This table includes only overall and not stratified seroprevalence measures.

View this table:
Table S5.

Studies reporting HSV-2 seroprevalence in Southern Africa. This table includes only overall and not stratified seroprevalence measures,

View this table:
Table S6.

Studies reporting HSV-2 seroprevalence in Western Africa. This table includes only overall and not stratified seroprevalence measures.

View this table:
Table S7.

Studies reporting HSV-2 seroprevalence in Central Africa. This table includes only overall and not stratified seroprevalence measures.

View this table:
Table S8.

Studies reporting HSV-2 seroprevalence across several regions in sub-Saharan Africa. This table includes only overall and not stratified seroprevalence measures.

View this table:
Table S9.

Pooled mean estimates for herpes simplex virus type 2 seroprevalence among general populations by sex stratification in sub-Saharan Africa.

Figure S2.
Figure S2.
Figure S2.
Figure S2.
Figure S2.
Figure S2.
Figure S2.
Figure S2.
Figure S2.
Figure S2.
Figure S2.
Figure S2.
Figure S2.
Figure S2.

Forest plots presenting the outcomes of the pooled mean herpes simplex virus type 2 (HSV-2) seroprevalence among the different at risk populations across the sub-Saharan Africa subregions.

View this table:
Table S10.

Univariable and multivariable meta-regression analyses for herpes simplex virus type 2 seroprevalence among the different at risk populations in sub-Saharan Africa using the year of data collection as a categorical variable or as a linear term (in replacement of year of publication).

View this table:
Table S11.

Studies reporting proportions of HSV-2 virus isolation in clinically-diagnosed genital ulcer disease and in clinically-diagnosed genital herpes in sub-Saharan Africa.

Figure S3.
Figure S3.
Figure S3.

Forest plots presenting the outcomes of the pooled mean proportions of HSV-2 virus isolation in clinically-diagnosed genital ulcer disease (GUD) and in clinically-diagnosed genital herpes in sub-Saharan Africa.

View this table:
Table S12.

Summary of the precision assessment and risk of bias assessment for the studies reporting HSV-2 seroprevalence in sub-Saharan Africa.

Acknowledgements

The authors gratefully acknowledge Professor Emeritus Rhoda Ashley Morrow from the University of Washington, for her support in assessing the quality of study diagnostic methods. The authors are also grateful for Ms. Adona Canlas for administrative support. The authors are grateful for pilot funding by the Biomedical Research Program and infrastructure support provided by the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar. This publication was made also possible by NPRP grant number 9-040-3-008 from the Qatar National Research Fund (a member of Qatar Foundation). The findings achieved herein are solely the responsibility of the authors. KL thanks the National Institute for Health Research, Health Protection Research Unit in Evaluation of Interventions at the University of Bristol, in partnership with Public Health England, for research support. The authors alone are responsible for the views expressed in this article and they do not necessarily represent the views, decisions or policies of the institutions with which they are affiliated, the NHS, the NIHR, the Department of Health and Social Care or Public Health England.

References

  1. 1.↵
    James C, Harfouche M, Welton NJ, Turner KME, Abu-Raddad LJ, Gottlieb SL, et al. Herpes simplex virus: global infection prevalence and incidence estimates, 2016. Bulletin of the World Health Organization. 2020;98(5):315–29.
    OpenUrlPubMed
  2. 2.↵
    Ahmed HJ, Mbwana J, Gunnarsson E, Ahlman K, Guerino C, Svensson LA, et al. Etiology of genital ulcer disease and association with human immunodeficiency virus infection in two tanzanian cities. Sex Transm Dis. 2003;30(2):114–9.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    Gupta R, Warren T, Wald A. Genital herpes. Lancet. 2007;370(9605):2127–37.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.
    Halioua B, Malkin JE. Epidemiology of genital herpes - recent advances. Eur J Dermatol. 1999;9(3):177–84.
    OpenUrlPubMedWeb of Science
  5. 5.
    Mertz KJ, Trees D, Levine WC, Lewis JS, Litchfield B, Pettus KS, et al. Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group. J Infect Dis. 1998;178(6):1795–8.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.
    Morse SA. Etiology of genital ulcer disease and its relationship to HIV infection. Sex Transm Dis. 1999;26(1):63–5.
    OpenUrlPubMedWeb of Science
  7. 7.
    O’Farrell N. Increasing prevalence of genital herpes in developing countries: implications for heterosexual HIV transmission and STI control programmes. Sex Transm Infect. 1999;75(6):377–84.
    OpenUrlAbstract
  8. 8.↵
    Weiss HA, Buve A, Robinson NJ, Van Dyck E, Kahindo M, Anagonou S, et al. The epidemiology of HSV-2 infection and its association with HIV infection in four urban African populations. AIDS. 2001;15 Suppl 4:S97–108.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    Looker KJ, Magaret AS, May MT, Turner KME, Vickerman P, Newman LM, et al. First estimates of the global and regional incidence of neonatal herpes infection. Lancet Glob Health. 2017;5(3):e300–e9.
    OpenUrl
  10. 10.↵
    Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS. 2006;20(1):73–83.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    Abu-Raddad LJ, Magaret AS, Celum C, Wald A, Longini Jr IM, Self SG, et al. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PloS one. 2008;3(5).
  12. 12.↵
    Looker KJ, Elmes JAR, Gottlieb SL, Schiffer JT, Vickerman P, Turner KME, et al. Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis. Lancet Infect Dis. 2017;17(12):1303–16.
    OpenUrlCrossRefPubMed
  13. 13.↵
    Looker KJ, Welton NJ, Sabin KM, Dalal S, Vickerman P, Turner KM, et al. Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data. The Lancet Infectious Diseases. 2020;20(2):240–9.
    OpenUrl
  14. 14.↵
    Omori R, Nagelkerke N, Abu-Raddad LJ. HIV and herpes simplex virus type 2 epidemiological synergy: misguided observational evidence? A modelling study. Sexually transmitted infections. 2018;94(5):372–6.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Annals of internal medicine. 1994;121(11):847–54.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    Wald A, Zeh J, Selke S, Warren T, Ryncarz AJ, Ashley R, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. New England Journal of Medicine. 2000;342(12):844–50.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    Wald A, Krantz E, Selke S, Lairson E, Morrow RA, Zeh J. Knowledge of partners’ genital herpes protects against herpes simplex virus type 2 acquisition. The Journal of infectious diseases. 2006;194(1):42–52.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    Wald A, Langenberg AG, Link K, Izu AE, Ashley R, Warren T, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. Jama. 2001;285(24):3100–6.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    Abu-Raddad LJ, Schiffer JT, Ashley R, Mumtaz G, Alsallaq RA, Akala FA, et al. HSV-2 serology can be predictive of HIV epidemic potential and hidden sexual risk behavior in the Middle East and North Africa. Epidemics. 2010;2(4):173–82.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    Omori R, Abu-Raddad LJ. Sexual network drivers of HIV and herpes simplex virus type 2 transmission. AIDS. 2017;31(12):1721–32.
    OpenUrl
  21. 21.
    van de Laar MJ, Termorshuizen F, Slomka MJ, van Doornum GJ, Ossewaarde JM, Brown DW, et al. Prevalence and correlates of herpes simplex virus type 2 infection: evaluation of behavioural risk factors. Int J Epidemiol. 1998;27(1):127–34.
    OpenUrlCrossRefPubMed
  22. 22.
    Cowan FM, Johnson AM, Ashley R, Corey L, Mindel A. Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations. BMJ. 1994;309(6965):1325–9.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    Obasi A, Mosha F, Quigley M, Sekirassa Z, Gibbs T, Munguti K, et al. Antibody to herpes simplex virus type 2 as a marker of sexual risk behavior in rural Tanzania. J Infect Dis. 1999;179(1):16–24.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    Kouyoumjian SP, Heijnen M, Chaabna K, Mumtaz GR, Omori R, Vickerman P, et al. Global population-level association between herpes simplex virus 2 prevalence and HIV prevalence. Aids. 2018;32(10):1343–52.
    OpenUrlPubMed
  25. 25.↵
    World Health Organization. Global health sector strategy on sexually transmitted infections 2016-2021: toward ending STIs. World Health Organization; 2016.
  26. 26.↵
    Gottlieb SL, Deal CD, Giersing B, Rees H, Bolan G, Johnston C, et al. The global roadmap for advancing development of vaccines against sexually transmitted infections: Update and next steps. Vaccine. 2016;34(26):2939–47.
    OpenUrlCrossRefPubMed
  27. 27.↵
    Gottlieb SL, Giersing B, Boily MC, Chesson H, Looker KJ, Schiffer J, et al. Modelling efforts needed to advance herpes simplex virus (HSV) vaccine development: Key findings from the World Health Organization Consultation on HSV Vaccine Impact Modelling. Vaccine. 2017.
  28. 28.↵
    UNAIDS. Global HIV/AIDS response:UNAIDS report on the global AIDS epidemic 2013 (available at: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf, accessed April 2014). 2013.
  29. 29.↵
  30. 30.↵
    Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions: John Wiley & Sons; 2011.
  31. 31.↵
    Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS med. 2009;6(7):e1000097.
    OpenUrlCrossRefPubMed
  32. 32.↵
    Chaabane S, Harfouche M, Chemaitelly H, Schwarzer G, Abu-Raddad LJ. Herpes simplex virus type 1 epidemiology in the Middle East and North Africa: systematic review, meta-analyses, and meta-regressions. Scientific reports. 2019;9(1):1–11.
    OpenUrl
  33. 33.↵
    Harfouche M, Chemaitelly H, Abu-Raddad LJ. Herpes simplex virus type 1 epidemiology in Africa: Systematic review, meta-analyses, and meta-regressions. J Infect. 2019;79(4):289–99.
    OpenUrlPubMed
  34. 34.
    Khadr L, Harfouche M, Omori R, Schwarzer G, Chemaitelly H, Abu-Raddad LJ. The epidemiology of herpes simplex virus type 1 in Asia: systematic review, meta-analyses, and meta-regressions. Clinical Infectious Diseases. 2018;68(5):757–72.
    OpenUrl
  35. 35.
    Sukik L, Alyafei M, Harfouche M, Abu-Raddad LJ. Herpes simplex virus type 1 epidemiology in Latin America and the Caribbean: Systematic review and meta-analytics. PloS one. 2019;14(4):e0215487.
    OpenUrlCrossRef
  36. 36.↵
    Yousuf W, Ibrahim H, Harfouche M, Abu Hijleh F, Abu-Raddad L. Herpes simplex virus type 1 in Europe: systematic review, meta-analyses and meta-regressions. BMJ Glob Health. 2020;5(7).
  37. 37.↵
    World Health Organization. WHO regional offices, (Available at: http://www.who.int/about/regions/en/, Accessed in May, 2017) 2017 [
  38. 38.↵
    Ashley-Morrow R, Nollkamper J, Robinson NJ, Bishop N, Smith J. Performance of focus ELISA tests for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse geographical locations. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2004;10(6):530–6.
    OpenUrl
  39. 39.↵
    Ashley RL. Performance and use of HSV type-specific serology test kits. Herpes. 2002;9(2):38–45.
    OpenUrlPubMed
  40. 40.↵
    Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26(4):404–13.
    OpenUrlCrossRef
  41. 41.↵
    Borenstein M H. L. V., Higgins, J. P. T. and Rothstein, H.R. Introduction to Meta-Analysis Chichester, UK: John Wiley & Sons, Ltd; 2009.
  42. 42.↵
    Schwarzer G. meta: An R package for meta-analysis. R news. 2007;7(3):40–5.
    OpenUrl
  43. 43.↵
    Freeman MF, Tukey JW. Transformations related to the angular and the square root. The Annals of Mathematical Statistics. 1950:607–11.
  44. 44.↵
    Schwarzer G, Chemaitelly H, Abu-Raddad LJ, Rücker G. Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions. Research synthesis methods. 2019;10(3):476–83.
    OpenUrlCrossRef
  45. 45.↵
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ: British Medical Journal. 2003;327(7414):557.
    OpenUrlCrossRefPubMedWeb of Science
  46. 46.↵
    RStudio Team. RStudio: Integrated Development for R. RStudio, Inc., Boston, MA URL http://www.rstudio.com/. 2015.
  47. 47.↵
    StataCorp. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP. 2015.
  48. 48.↵
    Harbord RM, Higgins JPT. Meta-regression in Stata. Stata Journal. 2008;8(4):493–519.
    OpenUrlWeb of Science
  49. 49.↵
    Aryee EA, Bailey RL, Natividad-Sancho A, Kaye S, Holland MJ. Detection, quantification and genotyping of Herpes Simplex Virus in cervicovaginal secretions by real-time PCR: a cross sectional survey. Virol J. 2005;2(1):61.
    OpenUrlCrossRefPubMed
  50. 50.
    Austrian K, Hewett PC, Soler-Hampejsek E, Bozzani F, Behrman JR, Digitale J. Adolescent Girls Empowerment Programme: research and evaluation mid-term technical report. 2016.
  51. 51.
    Cisse BC, Zaba F, Meite S, Mlan A, Inwoley K, Kouassi M’Bengue A, et al. Seroprevalence of herpes simplex virus 2 infection among pregnant women in urban health training Yopougon-Attie (Cote D’ivoire). Academic Journals. 2015;6(3):17–21.
    OpenUrl
  52. 52.
    Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infectious Diseases. 2012;12(1):19–26.
    OpenUrlCrossRefPubMedWeb of Science
  53. 53.
    Jespers V, Crucitti T, Menten J, Verhelst R, Mwaura M, Mandaliya K, et al. Prevalence and correlates of bacterial vaginosis in different sub-populations of women in sub-Saharan Africa: a cross-sectional study. PLoS One. 2014;9(10):e109670.
    OpenUrlCrossRefPubMed
  54. 54.
    Low AJ, Clayton T, Konate I, Nagot N, Ouedraogo A, Huet C, et al. Genital warts and infection with human immunodeficiency virus in high-risk women in Burkina Faso: a longitudinal study. BMC Infect Dis. 2011;11(1):20.
    OpenUrlCrossRefPubMed
  55. 55.
    Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine. 2015;372(6):509–18.
    OpenUrlCrossRefPubMed
  56. 56.
    McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet. 2010;376(9749):1329–37.
    OpenUrlCrossRefPubMedWeb of Science
  57. 57.
    MOH Uganda, ORC Macro. Uganda HIV/AIDS sero-behavioural survey: 2004-2005. Calverton, Maryland, USA: Ministry of Health and ORC Macro.; 2006.
  58. 58.
    NASCOP (National AIDS/STI Control Program). 2007 Kenya AIDS Indicator Survey: Final Report. Nairobe, Kenya; September 2009.
  59. 59.
    Odebisi-Omokanye M, Udeze A, Akanbi K, Jimoh N, Imam M. Serosurvey of Herpes Simplex Virus type-2 infection among HIV Infected Individuals Accessing a Secondary Health Care Facility in Kwara State, North Central Nigeria. Nig J Pure & Appl Sci. 2017;30(2).
  60. 60.
    Priddy FH, Wakasiaka S, Hoang TD, Smith DJ, Farah B, del Rio C, et al. Anal sex, vaginal practices, and HIV incidence in female sex workers in urban Kenya: implications for the development of intravaginal HIV prevention methods. AIDS Res Hum Retroviruses. 2011;27(10):1067–72.
    OpenUrlPubMed
  61. 61.↵
    Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Lancet. 2019;394(10195):303–13.
    OpenUrlCrossRefPubMed
  62. 62.↵
    UNAIDS/WHO. Global HIV/AIDS response:Epidemic update and health sector progress towards Universal Access (available at: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/20111130_UA_Report_en.pdf). 2011.
  63. 63.↵
    Garnett GP, Gregson S, Stanecki KA. Criteria for detecting and understanding changes in the risk of HIV infection at a national level in generalised epidemics. Sex Transm Infect. 2006;82 Suppl 1:i48–51.
    OpenUrlAbstract/FREE Full Text
  64. 64.↵
    Walker PT, Hallett TB, White PJ, Garnett GP. Interpreting declines in HIV prevalence: impact of spatial aggregation and migration on expected declines in prevalence. Sex Transm Infect. 2008;84 Suppl 2:ii42–8.
    OpenUrlAbstract/FREE Full Text
  65. 65.↵
    UNAIDS. Trends in HIV incidence and prevalence: natural course of the epidemic or results of behavioural change?; 1999.
  66. 66.↵
    Nagelkerke N, de Vlas SJ, Jha P, Luo M, Plummer FA, Kaul R. Heterogeneity in host HIV susceptibility as a potential contributor to recent HIV prevalence declines in Africa. Aids. 2009;23(1):125–30.
    OpenUrlCrossRefPubMedWeb of Science
  67. 67.↵
    Nagelkerke NJ, Arora P, Jha P, Williams B, McKinnon L, de Vlas SJ. The rise and fall of HIV in high-prevalence countries: a challenge for mathematical modeling. PLoS computational biology. 2014;10(3):e1003459.
    OpenUrl
  68. 68.↵
    Hallett TB, Gregson S, Mugurungi O, Gonese E, Garnett GP. Assessing evidence for behaviour change affecting the course of HIV epidemics: a new mathematical modelling approach and application to data from Zimbabwe. Epidemics. 2009;1(2):108–17.
    OpenUrlCrossRefPubMedWeb of Science
  69. 69.
    Hallett TB, Aberle-Grasse J, Bello G, Boulos LM, Cayemittes MP, Cheluget B, et al. Declines in HIV prevalence can be associated with changing sexual behaviour in Uganda, urban Kenya, Zimbabwe, and urban Haiti. Sex Transm Infect. 2006;82 Suppl 1:i1–8.
    OpenUrlAbstract/FREE Full Text
  70. 70.
    Kilian AH, Gregson S, Ndyanabangi B, Walusaga K, Kipp W, Sahlmuller G, et al. Reductions in risk behaviour provide the most consistent explanation for declining HIV-1 prevalence in Uganda. Aids. 1999;13(3):391–8.
    OpenUrlCrossRefPubMedWeb of Science
  71. 71.↵
    Awad SF, Abu-Raddad LJ. Could there have been substantial declines in sexual risk behavior across sub-Saharan Africa in the mid-1990s? Epidemics. 2014;8:9–17.
    OpenUrl
  72. 72.↵
    Ayoub HH, Amara I, Awad SF, Chemaitelly H, Abu-Raddad LJ. Analytic characterization of the herpes simplex virus type 2 epidemic in the United States, 1950-2050. Under Review.
  73. 73.↵
    Low N, Broutet N, Adu-Sarkodie Y, Barton P, Hossain M, Hawkes S. Global control of sexually transmitted infections. The Lancet. 2006;368(9551):2001–16.
    OpenUrlCrossRef
  74. 74.↵
    Smolak A, Chemaitelly H, Hermez JG, Low N, Abu-Raddad LJ. Epidemiology of chlamydia trachomatis in the Middle East and North Africa: a systematic review, meta-analysis, and meta-regression. The Lancet Global Health. 2019;7(9):e1197–e225.
    OpenUrl
  75. 75.↵
    UNAIDS. Global HIV & AIDS statistics — 2019 fact sheet 2019 [Available from: https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf, Accessed in March, 2020.
  76. 76.↵
    Cuadros DF, Awad SF, Abu-Raddad LJ. Mapping HIV clustering: a strategy for identifying populations at high risk ofHIV infection in sub-Saharan Africa. International journal of health geographics. 2013;12(1):28.
    OpenUrl
  77. 77.↵
    McQuillan GM, Kruszon-Moran D, Flagg EW, Paulose-Ram R. Prevalence of herpes simplex virus type 1 and type 2 in persons aged 14-49: United States, 2015-2016. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; 2018.
  78. 78.↵
    Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med. 1992;116(3):197–202.
    OpenUrlCrossRefPubMedWeb of Science
  79. 79.↵
    Looker KJ, Johnston C, Welton NJ, James C, Vickerman P, Turner KM, et al. The global and regional burden of genital ulcer disease due to herpes simplex virus: a natural history modelling study. BMJ global health. 2020;5(3):e001875.
    OpenUrlAbstract/FREE Full Text
  80. 80.↵
    Korenromp EL, Mahiané SG, Nagelkerke N, Taylor MM, Williams R, Chico RM, et al. Syphilis prevalence trends in adult women in 132 countries–estimations using the Spectrum Sexually Transmitted Infections model. Scientific reports. 2018;8(1):1–10.
    OpenUrl
  81. 81.↵
    Smolak A, Rowley J, Nagelkerke N, Kassebaum NJ, Chico RM, Korenromp EL, et al. Trends and predictors of syphilis prevalence in the general population: global pooled analyses of 1103 prevalence measures including 136 million syphilis tests. Clinical Infectious Diseases. 2018;66(8):1184–91.
    OpenUrlCrossRefPubMed
  82. 82.↵
    Ayoub HH, Chemaitelly H, Abu-Raddad LJ. Epidemiological Impact of Novel Preventive and Therapeutic HSV-2 Vaccination in the United States: Mathematical Modeling Analyses. Vaccines. 2020;8(3):366.
    OpenUrl
  83. 83.↵
    World Health Organization. World Health Organization preferred product characteristics for herpes 2 simplex virus vaccines. https://www.who.int/immunization/research/ppc-tpp/HSV_Vaccine_PPCs_for_Public_Comment.pdf. 2019.

References

  1. 1.
    Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine. 2009;6(7):e1000097.
    OpenUrl
  2. 2.
    West Africa Brief (Actualite Ouest-Africaine). The six regions of the African Union 2017 [Available from: http://www.west-africa-brief.org/content/en/six-regions-african-union, Accessed on June, 2019.
  3. 3.
    World Bank. World Bank Country and Lending Groups (Available at: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups. Accessed in June 2017) 2017 [
  4. 4.
    Abdool Karim Q, Kharsany AB, Leask K, Ntombela F, Humphries H, Frohlich JA, et al. Prevalence of HIV, HSV-2 and pregnancy among high school students in rural KwaZulu-Natal, South Africa: a bio-behavioural cross-sectional survey. Sexually transmitted infections. 2014;90(8):620–6.
    OpenUrlAbstract/FREE Full Text
  5. 5.
    Akinyi B, Odhiambo C, Otieno F, Inzaule S, Oswago S, Kerubo E, et al. Prevalence, incidence and correlates of HSV-2 infection in an HIV incidence adolescent and adult cohort study in western Kenya. PLoS One. 2017;12(6):e0178907.
    OpenUrlCrossRefPubMed
  6. 6.
    Biraro S, Kamali A, White R, Karabarinde A, Nsiimire Ssendagala J, Grosskurth H, et al. Effect of HSV-2 on population-level trends in HIV incidence in Uganda between 1990 and 2007. Tropical medicine & international health : TM & IH. 2013;18(10):1257–66.
    OpenUrl
  7. 7.
    De Baetselier I, Menten J, Cuylaerts V, Ahmed K, Deese J, Van Damme L, et al. Prevalence and incidence estimation of HSV-2 by two IgG ELISA methods among South African women at high risk of HIV. PLoS One. 2015;10(3):e0120207.
    OpenUrl
  8. 8.
    del Mar Pujades Rodriguez M, Obasi A, Mosha F, Todd J, Brown D, Changalucha J, et al. Herpes simplex virus type 2 infection increases HIV incidence: a prospective study in rural Tanzania. Aids. 2002;16(3):451–62.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.
    Hallfors DD, Cho H, Hartman S, Mbai I, Ouma CA, Halpern CT. Process Evaluation of a Clinical Trial to Test School Support as HIV Prevention Among Orphaned Adolescents in Western Kenya. Prevention science : the official journal of the Society for Prevention Research. 2017;18(8):955–63.
    OpenUrl
  10. 10.
    Heffron R, Chao A, Mwinga A, Sinyangwe S, Sinyama A, Ginwalla R, et al. High prevalent and incident HIV-1 and herpes simplex virus 2 infection among male migrant and non-migrant sugar farm workers in Zambia. Sexually transmitted infections. 2011;87(4):283–8.
    OpenUrlAbstract/FREE Full Text
  11. 11.
    Jewkes R, Nduna M, Levin J, Jama N, Dunkle K, Puren A, et al. Impact of stepping stones on incidence of HIV and HSV-2 and sexual behaviour in rural South Africa: cluster randomised controlled trial. BMJ (Clinical research ed). 2008;337:a506.
  12. 12.
    Kamali A, Nunn AJ, Mulder DW, Van Dyck E, Dobbins JG, Whitworth JA. Seroprevalence and incidence of genital ulcer infections in a rural Ugandan population. Sexually transmitted infections. 1999;75(2):98–102.
    OpenUrlAbstract
  13. 13.
    Kamali A, Quigley M, Nakiyingi J, Kinsman J, Kengeya-Kayondo J, Gopal R, et al. Syndromic management of sexually-transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: a community randomised trial. Lancet (London, England). 2003;361(9358):645–52.
    OpenUrl
  14. 14.
    Kebede Y, Dorigo-Zetsma W, Mengistu Y, Mekonnen Y, Schaap A, Wolday D, et al. Transmission of herpes simplex virus Type 2 among factory workers in Ethiopia. The Journal of infectious diseases. 2004;190(2):365–72.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.
    McFarland W, Gwanzura L, Bassett MT, Machekano R, Latif AS, Ley C, et al. Prevalence and incidence of herpes simplex virus type 2 infection among male Zimbabwean factory workers. The Journal of infectious diseases. 1999;180(5):1459–65.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.
    Mensch BS, Grant MJ, Soler-Hampejsek E, Kelly CA, Chalasani S, Hewett PC. Does schooling protect sexual health? The association between three measures of education and STIs among adolescents in Malawi. Population studies. 2020;74(2):241–61.
    OpenUrl
  17. 17.
    Munjoma MW, Kurewa EN, Mapingure MP, Mashavave GV, Chirenje MZ, Rusakaniko S, et al. The prevalence, incidence and risk factors of herpes simplex virus type 2 infection among pregnant Zimbabwean women followed up nine months after childbirth. BMC women’s health. 2010;10:2.
  18. 18.
    Nakubulwa S, Kaye DK, Bwanga F, Tumwesigye NM, Nakku-Joloba E, Mirembe FM. Incidence and risk factors for herpes simplex virus type 2 seroconversion among pregnant women in Uganda: A prospective study. Journal of infection in developing countries. 2016;10(10):1108–15.
    OpenUrl
  19. 19.
    Pettifor A, MacPhail C, Hughes JP, Selin A, Wang J, Gomez-Olive FX, et al. The effect of a conditional cash transfer on HIV incidence in young women in rural South Africa (HPTN 068): a phase 3, randomised controlled trial. The Lancet Global health. 2016;4(12):e978–e88.
    OpenUrl
  20. 20.
    Radebe F, Jemmott J, Klopper A, Jemmott L, O’Leary A, Ngwane Z, et al. Incidence and prevalence of sexually transmitted infections among school students in the eastern cape, South Africa. Sexually Transmitted Infections. 2011;87(SUPPL. 1):A30–A1.
    OpenUrlAbstract/FREE Full Text
  21. 21.
    Rosenberg M, Pettifor A, Duta M, Demeyere N, Wagner RG, Selin A, et al. Executive function associated with sexual risk in young South African women: Findings from the HPTN 068 cohort. PLoS One. 2018;13(4):e0195217.
    OpenUrl
  22. 22.
    Sobngwi-Tambekou J, Taljaard D, Lissouba P, Zarca K, Puren A, Lagarde E, et al. Effect of HSV-2 serostatus on acquisition of HIV by young men: results of a longitudinal study in Orange Farm, South Africa. The Journal of infectious diseases. 2009;199(7):958–64.
    OpenUrlCrossRefPubMed
  23. 23.
    Stoner MCD, Edwards JK, Miller WC, Aiello AE, Halpern CT, Julien A, et al. Does partner selection mediate the relationship between school attendance and HIV/Herpes simplex virus-2 among adolescent girls and young women in South Africa: An analysis of HIV prevention trials network 068 data. Journal of Acquired Immune Deficiency Syndromes. 2018;79(1):20–7.
    OpenUrl
  24. 24.
    Tobian AA, Charvat B, Ssempijja V, Kigozi G, Serwadda D, Makumbi F, et al. Factors associated with the prevalence and incidence of herpes simplex virus type 2 infection among men in Rakai, Uganda. The Journal of infectious diseases. 2009;199(7):945–9.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.
    Tobian AA, Kigozi G, Redd AD, Serwadda D, Kong X, Oliver A, et al. Male circumcision and herpes simplex virus type 2 infection in female partners: a randomized trial in Rakai, Uganda. The Journal of infectious diseases. 2012;205(3):486–90.
    OpenUrlCrossRefPubMed
  26. 26.
    van de Wijgert JH, Morrison CS, Brown J, Kwok C, Van Der Pol B, Chipato T, et al. Disentangling contributions of reproductive tract infections to HIV acquisition in African Women. Sexually transmitted diseases. 2009;36(6):357–64.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.
    Wagner HU, Van Dyck E, Roggen E, Nunn AJ, Kamali A, Schmid DS, et al. Seroprevalence and incidence of sexually transmitted diseases in a rural Ugandan population. International journal of STD & AIDS. 1994;5(5):332–7.
    OpenUrl
  28. 28.
    Kapiga SH, Sam NE, Shao JF, Masenga EJ, Renjifo B, Kiwelu IE, et al. Herpes simplex virus type 2 infection among bar and hotel workers in northern Tanzania: prevalence and risk factors. Sexually transmitted diseases. 2003;30(3):187–92.
    OpenUrlPubMedWeb of Science
  29. 29.
    Meque I, Dube K, Feldblum PJ, Clements AC, Zango A, Cumbe F, et al. Prevalence, incidence and determinants of herpes simplex virus type 2 infection among HIV-seronegative women at high-risk of HIV infection: a prospective study in Beira, Mozambique. PLoS One. 2014;9(2):e89705.
    OpenUrlCrossRefPubMed
  30. 30.
    Ondondo RO, Ng’ang’a ZW, Mpoke S, Kiptoo M, Bukusi E. Incidence and prevalence of herpes simplex virus type-2 infections among fishermen in Kisumu, Kenya. International Journal of Infectious Diseases. 2014;21(SUPPL. 1):422.
    OpenUrl
  31. 31.
    Riedner G, Hoffmann O, Rusizoka M, Mmbando D, Maboko L, Grosskurth H, et al. Decline in sexually transmitted infection prevalence and HIV incidence in female barworkers attending prevention and care services in Mbeya Region, Tanzania. Aids. 2006;20(4):609–15.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.
    Tassiopoulos KK, Seage G, 3rd., Sam N, Kiwelu I, Shao J, Ao TT, et al. Predictors of herpes simplex virus type 2 prevalence and incidence among bar and hotel workers in Moshi, Tanzania. The Journal of infectious diseases. 2007;195(4):493–501.
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.
    Braunstein SL, Ingabire CM, Kestelyn E, Uwizera AU, Mwamarangwe L, Ntirushwa J, et al. High human immunodeficiency virus incidence in a cohort of Rwandan female sex workers. Sexually transmitted diseases. 2011b;38(5):385–94.
    OpenUrlCrossRefPubMed
  34. 34.
    Chohan V, Baeten JM, Benki S, Graham SM, Lavreys L, Mandaliya K, et al. A prospective study of risk factors for herpes simplex virus type 2 acquisition among high-risk HIV-1 seronegative women in Kenya. Sexually transmitted infections. 2009;85(7):489–92.
    OpenUrlAbstract/FREE Full Text
  35. 35.
    Kaul R, Nagelkerke NJ, Kimani J, Ngugi E, Bwayo JJ, Macdonald KS, et al. Prevalent herpes simplex virus type 2 infection is associated with altered vaginal flora and an increased susceptibility to multiple sexually transmitted infections. The Journal of infectious diseases. 2007;196(11):1692–7.
    OpenUrlCrossRefPubMedWeb of Science
  36. 36.
    Masese L, Baeten JM, Richardson BA, Bukusi E, John-Stewart G, Jaoko W, et al. Incident herpes simplex virus type 2 infection increases the risk of subsequent episodes of bacterial vaginosis. The Journal of infectious diseases. 2014;209(7):1023–7.
    OpenUrlCrossRefPubMed
  37. 37.
    Ramjee G, Williams B, Gouws E, Van Dyck E, De Deken B, Karim SA. The impact of incident and prevalent herpes simplex virus-2 infection on the incidence of HIV-1 infection among commercial sex workers in South Africa. Journal of acquired immune deficiency syndromes (1999). 2005;39(3):333–9.
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.
    Traore IT, Hema MN, Meda N, Konate I, Some F, Bazie W, et al. Effect of a tailored intervention package on HIV-1 acquisition among young female sex workers in ouagadougou, Burkina Faso. Sexually Transmitted Infections. 2013;89(SUPPL. 1).
  39. 39.
    de Bruyn G, Shiboski S, van der Straten A, Blanchard K, Chipato T, Ramjee G, et al. The effect of the vaginal diaphragm and lubricant gel on acquisition of HSV-2. Sexually transmitted infections. 2011;87(4):301–5.
    OpenUrlAbstract/FREE Full Text
  40. 40.
    McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet (London, England). 2010;376(9749):1329–37.
    OpenUrl
  41. 41.
    Mehta SD, Moses S, Parker CB, Agot K, Maclean I, Bailey RC. Circumcision status and incident herpes simplex virus type 2 infection, genital ulcer disease, and HIV infection. Aids. 2012;26(9):1141–9.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.
    Mehta SD, Moses S, Agot K, Maclean I, Odoyo-June E, Li H, et al. Medical male circumcision and herpes simplex virus 2 acquisition: posttrial surveillance in Kisumu, Kenya. The Journal of infectious diseases. 2013;208(11):1869–76.
    OpenUrlCrossRefPubMed
  43. 43.
    Mlisana K, Naicker N, Werner L, Roberts L, Van Loggerenberg F, Baxter C, et al. Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa. Journal of Infectious Diseases. 2012;206(1):6–14.
    OpenUrlCrossRefPubMed
  44. 44.
    Perti T, Nyati M, Gray G, De Bruyn G, Selke S, Magaret A, et al. Frequent genital HSV-2 shedding among women during labor in Soweto, South Africa. Infectious diseases in obstetrics and gynecology. 2014;2014:258291.
  45. 45.
    Celum C, Morrow RA, Donnell D, Hong T, Hendrix CW, Thomas KK, et al. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial. Annals of internal medicine. 2014;161(1):11–9.
    OpenUrlCrossRefPubMed
  46. 46.
    Cowan FM, Humphrey JH, Ntozini R, Mutasa K, Morrow R, Iliff P. Maternal Herpes simplex virus type 2 infection, syphilis and risk of intra-partum transmission of HIV-1: results of a case control study. Aids. 2008a;22(2):193–201.
    OpenUrlCrossRefPubMedWeb of Science
  47. 47.
    Muiru AN, Guthrie BL, Bosire R, Merkel M, Liu AY, Choi RY, et al. Incident HSV-2 infections are common among HIV-1-discordant couples. The Journal of infectious diseases. 2013;208(7):1093–101.
    OpenUrlCrossRefPubMed
  48. 48.
    Okuku HS, Sanders EJ, Nyiro J, Ngetsa C, Ohuma E, McClelland RS, et al. Factors associated with herpes simplex virus type 2 incidence in a cohort of human immunodeficiency virus type 1-seronegative Kenyan men and women reporting high-risk sexual behavior. Sexually transmitted diseases. 2011;38(9):837–44.
    OpenUrlCrossRefPubMed
  49. 49.
    Amornkul PN, Vandenhoudt H, Nasokho P, Odhiambo F, Mwaengo D, Hightower A, et al. HIV prevalence and associated risk factors among individuals aged 13-34 years in Rural Western Kenya. PLoS One. 2009;4(7):e6470.
    OpenUrlCrossRefPubMed
  50. 50.
    Anjulo AA, Abebe T, Hailemichael F, Mihret A. Seroprevalence and risk factors of herpes simplex virus-2 among pregnant women attending antenatal care at health facilities in Wolaita zone, Ethiopia. Virology journal. 2016;13:43.
  51. 51.
    Behling J, Chan AK, Zeh C, Nekesa C, Heinzerling L. Evaluating HIV Prevention Programs: Herpes Simplex Virus Type 2 Antibodies as Biomarker for Sexual Risk Behavior in Young Adults in Resource-Poor Countries. PLoS One. 2015;10(5):e0128370.
    OpenUrl
  52. 52.
    Braunstein SL, Ingabire CM, Geubbels E, Vyankandondera J, Umulisa MM, Gahiro E, et al. High burden of prevalent and recently acquired HIV among female sex workers and female HIV voluntary testing center clients in Kigali, Rwanda. PLoS One. 2011a;6(9):e24321.
    OpenUrlPubMed
  53. 53.
    De Walque D, Dow WH, Nathan R, Abdul R, Abilahi F, Gong E, et al. Incentivising safe sex: A randomised trial of conditional cash transfers for HIV and sexually transmitted infection prevention in rural Tanzania. BMJ Open. 2012;2(1):000747.
    OpenUrl
  54. 54.
    Dhont N, van de Wijgert J, Luchters S, Muvunyi C, Vyankandondera J, Temmerman M. Sexual violence, HSV-2 and HIV are important predictors for infertility in Rwanda. Human reproduction (Oxford, England). 2010;25(10):2507–15.
    OpenUrlCrossRefPubMedWeb of Science
  55. 55.
    Doyle AM, Ross DA, Maganja K, Baisley K, Masesa C, Andreasen A, et al. Long-term biological and behavioural impact of an adolescent sexual health intervention in Tanzania: follow-up survey of the community-based MEMA kwa Vijana Trial. PLoS medicine. 2010;7(6):e1000287.
    OpenUrl
  56. 56.
    Duflo E, Dupas P, Kremer M. Education, HIV, and Early Fertility: Experimental Evidence from Kenya. The American economic review. 2015;105(9):2757–97.
    OpenUrlCrossRefPubMed
  57. 57.
    Ghebrekidan H, Ruden U, Cox S, Wahren B, Grandien M. Prevalence of herpes simplex virus types 1 and 2, cytomegalovirus, and varicella-zoster virus infections in Eritrea. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 1999;12(1):53–64.
    OpenUrl
  58. 58.
    Ghebremichael M, Paintsil E. High risk behaviors and sexually transmitted infections among men in Tanzania. AIDS and behavior. 2011;15(5):1026–32.
    OpenUrlCrossRefPubMedWeb of Science
  59. 59.
    Ghebremichael M, Habtzgi D, Paintsil E. Deciphering the epidemic synergy of herpes simplex virus type 2 (HSV-2) on human immunodeficiency virus type 1 (HIV-1) infection among women in sub-Saharan Africa. BMC research notes. 2012;5:451.
  60. 60.
    Gorander S, Mbwana J, Lyamuya E, Lagergard T, Liljeqvist JA. Mature glycoprotein g presents high performance in diagnosing herpes simplex virus type 2 infection in sera of different tanzanian cohorts. Clinical and vaccine immunology : CVI. 2006;13(6):633–9.
    OpenUrl
  61. 61.
    Guwatudde D, Wabwire-Mangen F, Eller LA, Eller M, McCutchan F, Kibuuka H, et al. Relatively low HIV infection rates in rural Uganda, but with high potential for a rise: a cohort study in Kayunga District, Uganda. PLoS One. 2009;4(1):e4145.
    OpenUrlCrossRefPubMed
  62. 62.
    Hallfors DD, Cho H, Mbai, II, Millimo BW, Atieno C, Okumu D, et al. Disclosure of HSV-2 serological test results in the context of an adolescent HIV prevention trial in Kenya. Sexually transmitted infections. 2015;91(6):395–400.
    OpenUrlAbstract/FREE Full Text
  63. 63.
    Hokororo A, Kihunrwa A, Hoekstra P, Kalluvya SE, Changalucha JM, Fitzgerald DW, et al. High prevalence of sexually transmitted infections in pregnant adolescent girls in Tanzania: a multi-community cross-sectional study. Sexually transmitted infections. 2015;91(7):473–8.
    OpenUrlAbstract/FREE Full Text
  64. 64.
    Holt BY, Effler P, Brady W, Friday J, Belay E, Parker K, et al. Planning STI/HIV prevention among refugees and mobile populations: situation assessment of Sudanese refugees. Disasters. 2003;27(1):1–15.
    OpenUrlCrossRefPubMed
  65. 65.
    Jespers V, Crucitti T, Menten J, Verhelst R, Mwaura M, Mandaliya K, et al. Prevalence and correlates of bacterial vaginosis in different sub-populations of women in sub-Saharan Africa: a cross-sectional study. PloS one. 2014;9(10):e109670.
    OpenUrlCrossRefPubMed
  66. 66.
    Kamali A, Kinsman J, Nalweyiso N, Mitchell K, Kanyesigye E, Kengeya-Kayondo JF, et al. A community randomized controlled trial to investigate impact of improved STD management and behavioural interventions on HIV incidence in rural Masaka, Uganda: trial design, methods and baseline findings. Tropical medicine & international health : TM & IH. 2002;7(12):1053–63.
    OpenUrl
  67. 67.
    Kapiga SH, Ewings FM, Ao T, Chilongani J, Mongi A, Baisley K, et al. The epidemiology of HIV and HSV-2 infections among women participating in microbicide and vaccine feasibility studies in Northern Tanzania. PLoS One. 2013;8(7):e68825.
    OpenUrlCrossRefPubMed
  68. 68.
    Kasubi MJ, Nilsen A, Marsden HS, Bergstrom T, Langeland N, Haarr L. Prevalence of antibodies against herpes simplex virus types 1 and 2 in children and young people in an urban region in Tanzania. Journal of clinical microbiology. 2006;44(8):2801–7.
    OpenUrlAbstract/FREE Full Text
  69. 69.
    Kuteesa MO, Weiss HA, Cook S, Seeley J, Ssentongo JN, Kizindo R, et al. Epidemiology of alcohol misuse and illicit drug use among young people aged 15-24 years in fishing communities in Uganda. International Journal of Environmental Research and Public Health. 2020;17 (7) (no pagination)(2401).
    OpenUrl
  70. 70.
    Mehta SD, Nordgren RK, Agingu W, Otieno F, Odongo W, Odhiambo F, et al. Sexual Quality of Life and Association With HIV and Sexually Transmitted Infections Among a Cohort of Heterosexual Couples in Kenya. Journal of Sexual Medicine. 2018;15(10):1446–55.
    OpenUrl
  71. 71.
    MOH Uganda, ORC Macro. Uganda HIV/AIDS sero-behavioural survey: 2004-2005. Calverton, Maryland, USA: Ministry of Health and ORC Macro.; 2006.
  72. 72.
    Msuya SE, Mbizvo E, Stray-Pedersen B, Sundby J, Sam NE, Hussain A. Reproductive tract infections and the risk of HIV among women in Moshi, Tanzania. Acta obstetricia et gynecologica Scandinavica. 2002;81(9):886–93.
    OpenUrlCrossRefPubMed
  73. 73.
    Msuya SE, Mbizvo EM, Stray-Pedersen B, Uriyo J, Sam NE, Rusakaniko S, et al. Decline in HIV prevalence among women of childbearing age in Moshi urban, Tanzania. International journal of STD & AIDS. 2007;18(10):680–7.
    OpenUrl
  74. 74.
    Msuya SE, Uriyo J, Hussain A, Mbizvo EM, Jeansson S, Sam NE, et al. Prevalence of sexually transmitted infections among pregnant women with known HIV status in northern Tanzania. Reproductive Health. 2009;6(1):4.
    OpenUrl
  75. 75.
    Nakku-Joloba E, Kambugu F, Wasubire J, Kimeze J, Salata R, Albert JM, et al. Sero-prevalence of herpes simplex type 2 virus (HSV-2) and HIV infection in Kampala, Uganda. African health sciences. 2014;14(4):782–9.
    OpenUrl
  76. 76.
    Nakubulwa S, Kaye DK, Bwanga F, Tumwesigye NM, Mirembe FM. Genital infections and risk of premature rupture of membranes in Mulago Hospital, Uganda: a case control study. BMC research notes. 2015;8:573.
  77. 77.
    NASCOP (National AIDS/STI Control Program). 2007 Kenya AIDS Indicator Survey: Final Report. Nairobe, Kenya; September 2009.
  78. 78.
    Nilsen A, Mwakagile D, Marsden H, Langeland N, Matre R, Haarr L. Prevalence of, and risk factors for, HSV-2 antibodies in sexually transmitted disease patients, healthy pregnant females, blood donors and medical students in Tanzania and Norway. Epidemiology and infection. 2005;133(5):915–25.
    OpenUrlCrossRefPubMed
  79. 79.
    Norris AH, Kitali AJ, Worby E. Alcohol and transactional sex: how risky is the mix? Social science & medicine (1982). 2009;69(8):1167–76.
    OpenUrlCrossRefPubMedWeb of Science
  80. 80.
    Nyiro JU, Sanders EJ, Ngetsa C, Wale S, Awuondo K, Bukusi E, et al. Seroprevalence, predictors and estimated incidence of maternal and neonatal Herpes Simplex Virus type 2 infection in semi-urban women in Kilifi, Kenya. BMC infectious diseases. 2011;11:155.
  81. 81.
    Oliver VO, Otieno G, Gvetadze R, Desai MA, Makanga M, Akelo V, et al. High prevalence of sexually transmitted infections among women screened for a contraceptive intravaginal ring study, Kisumu, Kenya, 2014. International Journal of STD and AIDS. 2018;29(14):1390–9.
    OpenUrl
  82. 82.
    Otieno FO, Ndivo R, Oswago S, Pals S, Chen R, Thomas T, et al. Correlates of prevalent sexually transmitted infections among participants screened for an HIV incidence cohort study in Kisumu, Kenya. International journal of STD & AIDS. 2015;26(4):225–37.
    OpenUrl
  83. 83.
    Reynolds SJ, Makumbi F, Newell K, Kiwanuka N, Ssebbowa P, Mondo G, et al. Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial. The Lancet Infectious diseases. 2012;12(6):441–8.
    OpenUrlCrossRefPubMedWeb of Science
  84. 84.
    Sivapalasingam S, McClelland RS, Ravel J, Ahmed A, Cleland CM, Gajer P, et al. An effective intervention to reduce intravaginal practices among HIV-1 uninfected Kenyan women. AIDS Research and Human Retroviruses. 2014;30(11):1046–54.
    OpenUrl
  85. 85.
    Tedla Y, Shibre T, Ali O, Tadele G, Woldeamanuel Y, Asrat D, et al. Serum antibodies to Toxoplasma gondii and Herpesvidae family viruses in individuals with schizophrenia and bipolar disorder: a case-control study. Ethiopian medical journal. 2011;49(3):211–20.
    OpenUrlPubMed
  86. 86.
    Todd J, Grosskurth H, Changalucha J, Obasi A, Mosha F, Balira R, et al. Risk factors influencing HIV infection incidence in a rural African population: a nested case-control study. The Journal of infectious diseases. 2006;193(3):458–66.
    OpenUrlCrossRefPubMedWeb of Science
  87. 87.
    Weiss HA, Buve A, Robinson NJ, Van Dyck E, Kahindo M, Anagonou S, et al. The epidemiology of HSV-2 infection and its association with HIV infection in four urban African populations. AIDS (London, England). 2001;15 Suppl 4:S97–108.
    OpenUrl
  88. 88.
    Winston SE, Chirchir AK, Muthoni LN, Ayuku D, Koech J, Nyandiko W, et al. Prevalence of sexually transmitted infections including HIV in street-connected adolescents in western Kenya. Sexually transmitted infections. 2015;91(5):353–9.
    OpenUrlAbstract/FREE Full Text
  89. 89.
    Yahya-Malima KI, Evjen-Olsen B, Matee MI, Fylkesnes K, Haarr L. HIV-1, HSV-2 and syphilis among pregnant women in a rural area of Tanzania: prevalence and risk factors. BMC infectious diseases. 2008;8:75.
    OpenUrlCrossRefPubMed
  90. 90.
    Yegorov S, Galiwango RM, Good SV, Mpendo J, Tannich E, Boggild AK, et al. Schistosoma mansoni infection and socio-behavioural predictors of HIV risk: a cross-sectional study in women from Uganda. BMC infectious diseases. 2018;18(1):586.
    OpenUrl
  91. 91.
    Ng’ayo OM, Bukusi E, R AM, Rowhani-Rahbar A, B AO, Friedrich D, et al. Sexual and demographic determinants for herpes simplex virus type 2 among fishermen along Lake Victoria, Kenya. Sexually transmitted infections. 2008;84(2):140–2.
    OpenUrlAbstract/FREE Full Text
  92. 92.
    Rakwar J, Jackson D, Maclean I, Obongo T, Bwayo J, Smith H, et al. Antibody to Haemophilus ducreyi among trucking company workers in Kenya. Sexually transmitted diseases. 1997;24(5):267–71.
    OpenUrlPubMedWeb of Science
  93. 93.
    Riedner G, Todd J, Rusizoka M, Mmbando D, Maboko L, Lyamuya E, et al. Possible reasons for an increase in the proportion of genital ulcers due to herpes simplex virus from a cohort of female bar workers in Tanzania. Sexually transmitted infections. 2007;83(2):91–6.
    OpenUrlAbstract/FREE Full Text
  94. 94.
    Vallely A, Kasindi S, Hambleton IR, Knight L, Chirwa T, Balira R, et al. Microbicides development program, Tanzania-baseline characteristics of an occupational cohort and reattendance at 3 months. Sexually transmitted diseases. 2007;34(9):638–43.
    OpenUrlCrossRefPubMedWeb of Science
  95. 95.
    Watson-Jones D, Weiss HA, Rusizoka M, Baisley K, Mugeye K, Changalucha J, et al. Risk factors for herpes simplex virus type 2 and HIV among women at high risk in northwestern Tanzania: preparing for an HSV-2 intervention trial. Journal of acquired immune deficiency syndromes (1999). 2007;46(5):631–42.
    OpenUrlCrossRefPubMedWeb of Science
  96. 96.
    Baeten JM, Benki S, Chohan V, Lavreys L, McClelland RS, Mandaliya K, et al. Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. Aids. 2007;21(13):1771–7.
    OpenUrlCrossRefPubMedWeb of Science
  97. 97.
    Baltzer H, Chege D, Rebbapragada A, Wachihi C, Shin LY, Kimani J, et al. Relative HIV resistance in kenyan sex workers is not due to an altered prevalence or mucosal immune impact of herpes simplex virus type 2 infection. Current HIV research. 2009;7(5):504–7.
    OpenUrlCrossRefPubMedWeb of Science
  98. 98.
    Masese L, Baeten JM, Richardson BA, Bukusi E, John-Stewart G, Graham SM, et al. Changes in the contribution of genital tract infections to HIV acquisition among Kenyan high-risk women from 1993 to 2012. Aids. 2015;29(9):1077–85.
    OpenUrl
  99. 99.
    Priddy FH, Wakasiaka S, Hoang TD, Smith DJ, Farah B, del Rio C, et al. Anal sex, vaginal practices, and HIV incidence in female sex workers in urban Kenya: implications for the development of intravaginal HIV prevention methods. AIDS Res Hum Retroviruses. 2011;27(10):1067–72.
    OpenUrlPubMed
  100. 100.
    Vandenhoudt HM, Langat L, Menten J, Odongo F, Oswago S, Luttah G, et al. Prevalence of HIV and other sexually transmitted infections among female sex workers in Kisumu, Western Kenya, 1997 and 2008. PLoS One. 2013;8(1):e54953.
    OpenUrl
  101. 101.
    Vandepitte J, Bukenya J, Weiss HA, Nakubulwa S, Francis SC, Hughes P, et al. HIV and other sexually transmitted infections in a cohort of women involved in high-risk sexual behavior in Kampala, Uganda. Sexually transmitted diseases. 2011;38(4):316–23.
    OpenUrlPubMed
  102. 102.
    Mehta SD, Moses S, Agot K, Agingu W, Parker C, Ndinya-Achola JO, et al. Herpes simplex virus type 2 infection among young uncircumcised men in Kisumu, Kenya. Sexually transmitted infections. 2008;84(1):42–8.
    OpenUrlAbstract/FREE Full Text
  103. 103.
    Nakubulwa S, Mirembe FM, Kaye DK, Kaddu-Mulindwa D. Association between HSV-2 and HIV serostatus in pregnant women of known HIV serostatus attending Mulago hospital antenatal clinic, Kampala, Uganda. Journal of infection in developing countries. 2009;3(10):803–6.
    OpenUrl
  104. 104.
    Serwadda D, Gray RH, Sewankambo NK, Wabwire-Mangen F, Chen MZ, Quinn TC, et al. Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda. The Journal of infectious diseases. 2003;188(10):1492–7.
    OpenUrlCrossRefPubMedWeb of Science
  105. 105.
    Baeten JM, McClelland RS, Corey L, Overbaugh J, Lavreys L, Richardson BA, et al. Vitamin A supplementation and genital shedding of herpes simplex virus among HIV-1-infected women: a randomized clinical trial. The Journal of infectious diseases. 2004;189(8):1466–71.
    OpenUrlCrossRefPubMedWeb of Science
  106. 106.
    Madebe R, Kiwelu I, Ndaro A, Francis F, Baraka V, Theilgaard Z, et al. Herpes Simplex virus type 2 seroprevalence and risk factors among adolescents and youth with HIV-1 in Northern, Tanzania. Journal of infection in developing countries. 2020;14(4):398–403.
    OpenUrl
  107. 107.
    McClelland RS, Wang CC, Overbaugh J, Richardson BA, Corey L, Ashley RL, et al. Association between cervical shedding of herpes simplex virus and HIV-1. Aids. 2002;16(18):2425–30.
    OpenUrlCrossRefPubMedWeb of Science
  108. 108.
    Roxby AC, Drake AL, John-Stewart G, Brown ER, Matemo D, Otieno PA, et al. Herpes simplex virus type 2, genital ulcers and HIV-1 disease progression in postpartum women. PLoS One. 2011;6(5):e19947.
    OpenUrlCrossRefPubMed
  109. 109.
    Langeland N, Haarr L, Mhalu F. Prevalence of HSV-2 antibodies among STD clinic patients in Tanzania. International journal of STD & AIDS. 1998;9(2):104–7.
    OpenUrl
  110. 110.
    Mostad SB, Kreiss JK, Ryncarz AJ, Mandaliya K, Chohan B, Ndinya-Achola J, et al. Cervical shedding of herpes simplex virus in human immunodeficiency virus-infected women: effects of hormonal contraception, pregnancy, and vitamin A deficiency. The Journal of infectious diseases. 2000;181(1):58–63.
    OpenUrlCrossRefPubMedWeb of Science
  111. 111.
    Mwansasu A, Mwakagile D, Haarr L, Langeland N. Detection of HSV-2 in genital ulcers from STD patients in Dar es Salaam, Tanzania. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2002;24(3):183–92.
    OpenUrl
  112. 112.
    Suntoke TR, Hardick A, Tobian AA, Mpoza B, Laeyendecker O, Serwadda D, et al. Evaluation of multiplex real-time PCR for detection of Haemophilus ducreyi, Treponema pallidum, herpes simplex virus type 1 and 2 in the diagnosis of genital ulcer disease in the Rakai District, Uganda. Sexually transmitted infections. 2009;85(2):97–101.
    OpenUrlAbstract/FREE Full Text
  113. 113.
    Kassa D, Gebremichael G, Tilahun T, Ayalkebet A, Abrha Y, Mesfin G, et al. Prevalence of sexually transmitted infections (HIV, hepatitis B virus, herpes simplex virus type 2, and syphilis) in pregnant women in Ethiopia: Trends over 10 years (2005-2014). International Journal of Infectious Diseases. 2019;79:50–7.
    OpenUrl
  114. 114.
    Abbai NS, Govender S, Nyirenda M. Herpes simplex virus-2 infections in pregnant women from Durban, South Africa: prevalence, risk factors and co-infection with HIV-1. Southern African Journal of Infectious Diseases. 2018.
  115. 115.
    Achilles SL, Mhlanga F, Dezzutti CS, Matubu AT, Stoner KA, Beamer M, et al. Differences in genital tract immune cell populations and innate cervicovaginal fluid anti-HIV activity among women from Zimbabwe and the United States. AIDS Research and Human Retroviruses. 2016;32(Supplement 1):78.
    OpenUrl
  116. 116.
    Austrian K, Hewett PC, Soler-Hampejsek E, Bozzani F, Behrman JR, Digitale J. Adolescent Girls Empowerment Programme: research and evaluation mid-term technical report. 2016.
  117. 117.
    Baird SJ, Garfein RS, McIntosh CT, Ozler B. Effect of a cash transfer programme for schooling on prevalence of HIV and herpes simplex type 2 in Malawi: a cluster randomised trial. Lancet (London, England). 2012;379(9823):1320–9.
    OpenUrl
  118. 118.
    Birdthistle IJ, Floyd S, Machingura A, Mudziwapasi N, Gregson S, Glynn JR. From affected to infected? Orphanhood and HIV risk among female adolescents in urban Zimbabwe. Aids. 2008;22(6):759–66.
    OpenUrlCrossRefPubMedWeb of Science
  119. 119.
    Bradley J, Floyd S, Piwowar-Manning E, Laeyendecker O, Young A, Bell-Mandla N, et al. Sexually transmitted bedfellows: Exquisite association between HIV and herpes simplex virus type 2 in 21 communities in Southern Africa in the HIV prevention trials network 071 (PopART) Study. Journal of Infectious Diseases. 2018;218(3):443–52.
    OpenUrl
  120. 120.
    Chatterjee K, Dandara C, Gyllensten U, van der Merwe L, Galal U, Hoffman M, et al. A Fas gene polymorphism influences herpes simplex virus type 2 infection in South African women. Journal of medical virology. 2010;82(12):2082–6.
    OpenUrlCrossRefPubMed
  121. 121.
    Cowan FM, Pascoe SJS, Langhaug LF, Dirawo J, Chidiya S, Jaffar S, et al. The Regai Dzive Shiri Project: A cluster randomised controlled trial to determine the effectiveness of a multi-component community-based HIV prevention intervention for rural youth in Zimbabwe - Study design and baseline results. Tropical Medicine and International Health. 2008b;13(10):1235–44.
    OpenUrlCrossRefWeb of Science
  122. 122.
    Crucitti T, Jespers V, Mulenga C, Khondowe S, Vandepitte J, Buve A. Non-sexual transmission of Trichomonas vaginalis in adolescent girls attending school in Ndola, Zambia. PLoS One. 2011;6(1):e16310.
    OpenUrlCrossRefPubMed
  123. 123.
    Delany-Moretlwe S, Jentsch U, Weiss H, Moyes J, Ashley-Morrow R, Stevens W, et al. Comparison of focus HerpesSelect and Kalon HSV-2 gG2 ELISA serological assays to detect herpes simplex virus type 2 antibodies in a South African population. Sexually transmitted infections. 2010;86(1):46–50.
    OpenUrlAbstract/FREE Full Text
  124. 124.
    Fearon E, Wiggins RD, Pettifor AE, MacPhail C, Kahn K, Selin A, et al. Associations between friendship characteristics and HIV and HSV-2 status amongst young South African women in HPTN-068. Journal of the International AIDS Society. 2017;20(4).
  125. 125.
    Ferrand RA, Munaiwa L, Matsekete J, Bandason T, Nathoo K, Ndhlovu CE, et al. Undiagnosed HIV infection among adolescents seeking primary health care in Zimbabwe. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2010a;51(7):844–51.
    OpenUrlCrossRefPubMedWeb of Science
  126. 126.
    Ferrand RA, Bandason T, Musvaire P, Larke N, Nathoo K, Mujuru H, et al. Causes of acute hospitalization in adolescence: burden and spectrum of HIV-related morbidity in a country with an early-onset and severe HIV epidemic: a prospective survey. PLoS medicine. 2010b;7(2):e1000178.
    OpenUrl
  127. 127.
    Francis SC, Mthiyane TN, Baisley K, McHunu SL, Ferguson JB, Smit T, et al. Prevalence of sexually transmitted infections among young people in South Africa: A nested survey in a health and demographic surveillance site. PLoS medicine. 2018;15(2):e1002512.
    OpenUrl
  128. 128.
    Glynn JR, Crampin AC, Ngwira BM, Ndhlovu R, Mwanyongo O, Fine PE. Herpes simplex virus type 2 trends in relation to the HIV epidemic in northern Malawi. Sexually transmitted infections. 2008;84(5):356–60.
    OpenUrlAbstract/FREE Full Text
  129. 129.
    Glynn JR, Kayuni N, Gondwe L, Price AJ, Crampin AC. Earlier menarche is associated with a higher prevalence of Herpes simplex type-2 (HSV-2) in young women in rural Malawi. eLife. 2014;3:e01604.
    OpenUrlCrossRefPubMed
  130. 130.
    Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. The Lancet Infectious diseases. 2011;11(7):507–15.
    OpenUrlCrossRefPubMedWeb of Science
  131. 131.
    Gregson S, Mason PR, Garnett GP, Zhuwau T, Nyamukapa CA, Anderson RM, et al. A rural HIV epidemic in Zimbabwe? Findings from a population-based survey. International journal of STD & AIDS. 2001;12(3):189–96.
    OpenUrl
  132. 132.
    Gwanzura L, Chigonda TG, Mvere D, De Villiers DM, Siziya S, Mason PR. The prevalence of Herpes simplex virus type-2 infection in blood donors in Harare, Zimbabwe. The Central African journal of medicine. 2002;48(3-4):38–42.
    OpenUrlPubMed
  133. 133.
    Hazel A, Foxman B, Low BS. Herpes simplex virus type 2 among mobile pastoralists in northwestern Namibia. Annals of human biology. 2015;42(6):543–51.
    OpenUrl
  134. 134.
    Kapina M, Reid C, Roman K, Cyrus-Cameron E, Kwiecien A, Weiss S, et al. HIV incidence rates and risk factors for urban women in Zambia: Preparing for a microbicide clinical trial. Sexually Transmitted Diseases. 2009;36(3):129–33.
    OpenUrlPubMed
  135. 135.
    Kenyon C, Colebunders R, Buve A, Hens N. Partner-concurrency associated with herpes simplex virus 2 infection in young South Africans. International journal of STD & AIDS. 2013;24(10):804–12.
    OpenUrl
  136. 136.
    Kharsany ABM, McKinnon LR, Lewis L, Cawood C, Khanyile D, Maseko DV, et al. Population prevalence of sexually transmitted infections in a high HIV burden district in KwaZulu-Natal, South Africa: Implications for HIV epidemic control. International Journal of Infectious Diseases. 2020;98:130–7.
    OpenUrl
  137. 137.
    Kjetland EF, Gwanzura L, Ndhlovu PD, Mduluza T, Gomo E, Mason PR, et al. Herpes simplex virus type 2 prevalence of epidemic proportions in rural Zimbabwean women: association with other sexually transmitted infections. Archives of gynecology and obstetrics. 2005;272(1):67–73.
    OpenUrlCrossRefPubMed
  138. 138.
    Kurewa NE, Mapingure MP, Munjoma MW, Chirenje MZ, Rusakaniko S, Stray-Pedersen B. The burden and risk factors of Sexually Transmitted Infections and Reproductive Tract Infections among pregnant women in Zimbabwe. BMC infectious diseases. 2010;10:127.
  139. 139.
    Luseno WK, Hallfors DD, Cho H, Iritani BJ, Adze J, Rusakaniko S, et al. Use of HIV and HSV-2 biomarkers in sub-saharan adolescent prevention research: a comparison of two approaches. The journal of primary prevention. 2014;35(3):181–91.
    OpenUrl
  140. 140.
    Mbizvo EM, Msuya Sia E, Stray-Pedersen B, Chirenje MZ, Munjoma M, Hussain A. Association of herpes simplex virus type 2 with the human immunodeficiency virus among urban women in Zimbabwe. International journal of STD & AIDS. 2002;13(5):343–8.
    OpenUrl
  141. 141.
    Menezes LJ, Pokharel U, Sudenga SL, Botha MH, Zeier M, Abrahamsen ME, et al. Patterns of prevalent HPV and STI co-infections and associated factors among HIV-negative young Western Cape, South African women: the EVRI trial. Sexually transmitted infections. 2018;94(1):55–61.
    OpenUrlAbstract/FREE Full Text
  142. 142.
    NIMH Collaborative HIV/STD Prevention Trial Group. Sexually transmitted disease and HIV prevalence and risk factors in concentrated and generalized HIV epidemic settings. AIDS. 2007;21 Suppl 2:S81–90.
    OpenUrl
  143. 143.
    Pascoe SJ, Langhaug LF, Mavhu W, Hargreaves J, Jaffar S, Hayes R, et al. Poverty, food insufficiency and HIV infection and sexual behaviour among young rural Zimbabwean women. PLoS One. 2015;10(1):e0115290.
    OpenUrlCrossRefPubMed
  144. 144.
    Price J, Pettifor A, Selin A, Wagner RG, MacPhail C, Agyei Y, et al. The association between perceived household educational support and HIV risk in young women in a rural South African community (HPTN 068): A cross sectional study. PloS one. 2019;14(1):e0210632.
    OpenUrl
  145. 145.
    Wand H, Ramjee G. The relationship between age of coital debut and HIV seroprevalence among women in Durban, South Africa: A cohort study. BMJ Open. 2012;2(1):000285.
    OpenUrl
  146. 146.
    Cowan FM, Hargrove JW, Langhaug LF, Jaffar S, Mhuriyengwe L, Swarthout TD, et al. The appropriateness of core group interventions using presumptive periodic treatment among rural Zimbabwean women who exchange sex for gifts or money. Journal of acquired immune deficiency syndromes (1999). 2005;38(2):202–7.
    OpenUrlCrossRefPubMedWeb of Science
  147. 147.
    Abdool Karim SS, Abdool Karim Q, Kharsany AB, Baxter C, Grobler AC, Werner L, et al. Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection. The New England journal of medicine. 2015;373(6):530–9.
    OpenUrlCrossRefPubMed
  148. 148.
    Balkus JE, Brown ER, Hillier SL, Coletti A, Ramjee G, Mgodi N, et al. Oral and injectable contraceptive use and HIV acquisition risk among women in four African countries: A secondary analysis of data from a microbicide trial. Contraception. 2016;93(1):25–31.
    OpenUrl
  149. 149.
    Barnabas SL, Dabee S, Passmore JS, Jaspan HB, Lewis DA, Jaumdally SZ, et al. Converging epidemics of sexually transmitted infections and bacterial vaginosis in southern African female adolescents at risk of HIV. International journal of STD & AIDS. 2018;29(6):531–9.
    OpenUrl
  150. 150.
    Benjamin RJ, Busch MP, Fang CT, Notari EP, Puren A, Schoub BD, et al. Human immunodeficiency virus-1 infection correlates strongly with herpes simplex virus-2 (genital herpes) seropositivity in South African and United States blood donations. Transfusion. 2008;48(2):295–303.
    OpenUrl
  151. 151.
    Gust DA, Soud F, Hardnett FP, Malotte CK, Rose C, Kebaabetswe P, et al. Evaluation of sexual risk behavior among study participants in the TDF2 PrEP study among heterosexual adults in Botswana. Journal of Acquired Immune Deficiency Syndromes. 2016;73(5):556–63.
    OpenUrl
  152. 152.
    Mavedzenge SN, Weiss HA, Montgomery ET, Blanchard K, de Bruyn G, Ramjee G, et al. Determinants of differential HIV incidence among women in three southern African locations. Journal of acquired immune deficiency syndromes (1999). 2011;58(1):89–99.
    OpenUrlCrossRefPubMed
  153. 153.
    Wand H, Ramjee G. Evaluating HIV prevention efforts using semiparametric regression models: Results from a large cohort of women participating in an HIV prevention trial from KwaZulu-Natal, South Africa. Journal of the International AIDS Society. 2013;16:18589.
    OpenUrl
  154. 154.
    Sutcliffe S, Taha TE, Kumwenda NI, Taylor E, Liomba GN. HIV-1 prevalence and herpes simplex virus 2, hepatitis C virus, and hepatitis B virus infections among male workers at a sugar estate in Malawi. Journal of acquired immune deficiency syndromes (1999). 2002;31(1):90–7.
    OpenUrlCrossRefPubMedWeb of Science
  155. 155.
    Lewis DA, Chirwa TF, Msimang VM, Radebe FM, Kamb ML, Firnhaber CS. Urethritis/cervicitis pathogen prevalence and associated risk factors among asymptomatic HIV-infected patients in South Africa. Sexually transmitted diseases. 2012;39(7):531–6.
    OpenUrlCrossRefPubMed
  156. 156.
    Lowe S, Mudzviti T, Mandiriri A, Shamu T, Mudhokwani P, Chimbetete C, et al. Sexually transmitted infections, the silent partner in HIV-infected women in Zimbabwe. Southern African Journal of HIV Medicine. 2019;20 (1) (no pagination)(a849).
    OpenUrl
  157. 157.
    Kufa T, Radebe F, Maseko V, Puren A, Kularatne R. Medical Male Circumcision and Associations Among Sexually Transmitted Infections Service Attendees. AIDS and behavior. 2020;24(5):1422–31.
    OpenUrl
  158. 158.
    Rabenau HF, Lennemann T, Kircher C, Gurtler L, Staszewski S, Preiser W, et al. Prevalence- and gender-specific immune response to opportunistic infections in HIV-infected patients in Lesotho. Sexually transmitted diseases. 2010;37(7):454–9.
    OpenUrlPubMed
  159. 159.
    Varo R, Buck WC, Kazembe PN, Phiri S, Andrianarimanana D, Weigel R. Seroprevalence of CMV, HSV-2 and HBV among HIV-Infected Malawian Children: A Cross-sectional Survey. Journal of tropical pediatrics. 2016;62(3):220–6.
    OpenUrlCrossRefPubMed
  160. 160.
    Chen CY, Ballard RC, Beck-Sague CM, Dangor Y, Radebe F, Schmid S, et al. Human immunodeficiency virus infection and genital ulcer disease in South Africa: the herpetic connection. Sexually transmitted diseases. 2000;27(1):21–9.
    OpenUrlCrossRefPubMedWeb of Science
  161. 161.
    Esber A, Rao N, Norris A, Carr Reese P, Kandodo J, Nampandeni P, et al. Intravaginal Practices and Prevalence of Sexual and Reproductive Tract Infections Among Women in Rural Malawi. Sexually transmitted diseases. 2016;43(12):750–5.
    OpenUrl
  162. 162.
    Hoyo C, Hoffman I, Moser BK, Hobbs MM, Kazembe P, Krysiak RG, et al. Improving the accuracy of syndromic diagnosis of genital ulcer disease in Malawi. Sexually transmitted diseases. 2005;32(4):231–7.
    OpenUrlCrossRefPubMedWeb of Science
  163. 163.
    Kularatne RS, Muller EE, Maseko DV, Kufa-Chakezha T, Lewis DA. Trends in the relative prevalence of genital ulcer disease pathogens and association with HIV infection in Johannesburg, South Africa, 2007-2015. PLoS One. 2018;13(4):e0194125.
    OpenUrl
  164. 164.
    Lewis DA, Pillay C, Mohlamonyane O, Vezi A, Mbabela S, Mzaidume Y, et al. The burden of asymptomatic sexually transmitted infections among men in Carletonville, South Africa: implications for syndromic management. Sexually transmitted infections. 2008;84(5):371–6.
    OpenUrlAbstract/FREE Full Text
  165. 165.
    Lewis DA, Marsh K, Radebe F, Maseko V, Hughes G. Trends and associations of Trichomonas vaginalis infection in men and women with genital discharge syndromes in Johannesburg, South Africa. Sexually transmitted infections. 2013;89(6):523–7.
    OpenUrlAbstract/FREE Full Text
  166. 166.
    Mhlongo S, Magooa P, Muller EE, Nel N, Radebe F, Wasserman E, et al. Etiology and STI/HIV coinfections among patients with urethral and vaginal discharge syndromes in South Africa. Sexually transmitted diseases. 2010;37(9):566–70.
    OpenUrlCrossRefPubMed
  167. 167.
    Morse SA, Trees DL, Htun Y, Radebe F, Orle KA, Dangor Y, et al. Comparison of clinical diagnosis and standard laboratory and molecular methods for the diagnosis of genital ulcer disease in Lesotho: association with human immunodeficiency virus infection. The Journal of infectious diseases. 1997;175(3):583–9.
    OpenUrlCrossRefPubMedWeb of Science
  168. 168.
    O’Farrell N, Morison L, Moodley P, Pillay K, Vanmali T, Quigley M, et al. High-risk sexual behaviour in men attending a sexually transmitted infection clinic in Durban, South Africa. Sexually transmitted infections. 2007;83(7):530–3.
    OpenUrlAbstract/FREE Full Text
  169. 169.
    Paz-Bailey G, Sternberg M, Puren AJ, Markowitz LE, Ballard R, Delany S, et al. Improvement in healing and reduction in HIV shedding with episodic acyclovir therapy as part of syndromic management among men: a randomized, controlled trial. The Journal of infectious diseases. 2009;200(7):1039–49.
    OpenUrlCrossRefPubMedWeb of Science
  170. 170.
    Phiri S, Zadrozny S, Weiss HA, Martinson F, Nyirenda N, Chen CY, et al. Etiology of genital ulcer disease and association with HIV infection in Malawi. Sexually transmitted diseases. 2013;40(12):923–8.
    OpenUrlCrossRefPubMed
  171. 171.
    Zimba TF, Apalata T, Sturm WA, Moodley P. Aetiology of sexually transmitted infections in Maputo, Mozambique. Journal of infection in developing countries. 2011;5(1):41–7.
    OpenUrl
  172. 172.
    Chattopadhyay K, Williamson AL, Hazra A, Dandara C. The combined risks of reduced or increased function variants in cell death pathway genes differentially influence cervical cancer risk and herpes simplex virus type 2 infection among black Africans and the Mixed Ancestry population of South Africa. BMC cancer. 2015;15:680.
    OpenUrl
  173. 173.
    Anaedobe CG, Ajani TA. Co-infection of herpes simplex virus type 2 and HIV infections among pregnant women in Ibadan, Nigeria. Journal of Global Infectious Diseases. 2019;11(1):19–24.
    OpenUrl
  174. 174.
    Ashley-Morrow R, Nollkamper J, Robinson NJ, Bishop N, Smith J. Performance of focus ELISA tests for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse geographical locations. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2004;10(6):530–6.
    OpenUrl
  175. 175.
    Behanzin L, Diabate S, Minani I, Lowndes CM, Boily MC, Labbe AC, et al. Decline in HIV Prevalence among Young Men in the General Population of Cotonou, Benin, 1998-2008. PLoS ONE. 2012;7(8):e43818.
    OpenUrlCrossRefPubMed
  176. 176.
    Cisse BC, Zaba F, Meite S, Mlan A, Inwoley K, Kouassi M’Bengue A, et al. Seroprevalence of herpes simplex virus 2 infection among pregnant women in urban health training Yopougon-Attie (Cote D’ivoire). Academic Journals. 2015;6(3):17–21.
    OpenUrl
  177. 177.
    Eltom MA, Mbulaiteye SM, Dada AJ, Whitby D, Biggar RJ. Transmission of human herpesvirus 8 by sexual activity among adults in Lagos, Nigeria. Aids. 2002;16(18):2473–8.
    OpenUrlCrossRefPubMedWeb of Science
  178. 178.
    Kane CT, Diawara S, Ndiaye HD, Diallo PA, Wade AS, Diallo AG, et al. Concentrated and linked epidemics of both HSV-2 and HIV-1/HIV-2 infections in Senegal: public health impacts of the spread of HIV. International journal of STD & AIDS. 2009;20(11):793–6.
    OpenUrl
  179. 179.
    Katz I, De Luca F, Dzudzor B, Sarpong BK, Osei-Appiah B, Azoulay D, et al. Seroprevalences of autoantibodies and anti-infectious antibodies among Ghana’s healthy population. Scientific reports. 2020;10(1):2814.
    OpenUrl
  180. 180.
    Kirakoya-Samadoulougou F, Nagot N, Defer MC, Yaro S, Fao P, Ilboudo F, et al. Epidemiology of herpes simplex virus type 2 infection in rural and Urban Burkina Faso. Sexually Transmitted Diseases. 2011;38(2):117–23.
    OpenUrlCrossRefPubMed
  181. 181.
    Lagarde E, Congo Z, Meda N, Baya B, Yaro S, Sangli G, et al. Epidemiology of HIV infection in urban Burkina Faso. International Journal of STD and AIDS. 2004;15(6):395–402.
    OpenUrl
  182. 182.
    Mawak JD, Dashe N, Atseye AB, Agabi YA, Zakeri H. Seroprevalence and co-infection of herpes simplex virus type 2 and human immunodeficiency virus in Nigeria. Shiraz E Medical Journal. 2012;13(1):33–9.
    OpenUrl
  183. 183.
    Patnaik P, Herrero R, Morrow RA, Munoz N, Bosch FX, Bayo S, et al. Type-specific seroprevalence of herpes simplex virus type 2 and associated risk factors in middle-aged women from 6 countries: the IARC multicentric study. Sexually transmitted diseases. 2007;34(12):1019–24.
    OpenUrlPubMed
  184. 184.
    Shaw M, van der Sande M, West B, Paine K, Ceesay S, Bailey R, et al. Prevalence of herpes simplex type 2 and syphilis serology among young adults in a rural Gambian community. Sexually transmitted infections. 2001;77(5):358–65.
    OpenUrlAbstract/FREE Full Text
  185. 185.
    Thomas JO, Herrero R, Omigbodun AA, Ojemakinde K, Ajayi IO, Fawole A, et al. Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. British journal of cancer. 2004;90(3):638–45.
    OpenUrlCrossRefPubMedWeb of Science
  186. 186.
    Walraven G, Scherf C, West B, Ekpo G, Paine K, Coleman R, et al. The burden of reproductive-organ disease in rural women in The Gambia, West Africa. Lancet (London, England). 2001;357(9263):1161–7.
    OpenUrl
  187. 187.
    Aho J, Koushik A, Coutlee F, Diakite SL, Rashed S. Prevalence of HIV, human papillomavirus type 16 and herpes simplex virus type 2 among female sex workers in Guinea and associated factors. International Journal of STD and AIDS. 2014;25(4):280–8.
    OpenUrl
  188. 188.
    Dada AJ, Ajayi AO, Diamondstone L, Quinn TC, Blattner WA, Biggar RJ. A serosurvey of Haemophilus ducreyi, syphilis, and herpes simplex virus type 2 and their association with human immunodeficiency virus among female sex workers in Lagos, Nigeria. Sexually transmitted diseases. 1998;25(5):237–42.
    OpenUrlCrossRefPubMedWeb of Science
  189. 189.
    Low AJ, Clayton T, Konate I, Nagot N, Ouedraogo A, Huet C, et al. Genital warts and infection with human immunodeficiency virus in high-risk women in Burkina Faso: a longitudinal study. BMC infectious diseases. 2011;11(1):20.
    OpenUrlCrossRefPubMed
  190. 190.
    Nagot N, Ouedraogo A, Ouangre A, Cartoux M, Defer MC, Meda N, et al. Is sexually transmitted infection management among sex workers still able to mitigate the spread of HIV infection in West Africa? Journal of Acquired Immune Deficiency Syndromes. 2005;39(4):454–8.
    OpenUrlCrossRefPubMedWeb of Science
  191. 191.
    Traore IT, Meda N, Hema NM, Ouedraogo D, Some F, Some R, et al. HIV prevention and care services for female sex workers: Efficacy of a targeted community-based intervention in Burkina Faso. Journal of the International AIDS Society. 2015;18(1):20088.
    OpenUrl
  192. 192.
    Wade AS, Kane CT, Diallo PA, Diop AK, Gueye K, Mboup S, et al. HIV infection and sexually transmitted infections among men who have sex with men in Senegal. Aids. 2005;19(18):2133–40.
    OpenUrlCrossRefPubMedWeb of Science
  193. 193.
    Camara M, Seydi M, Dieye TN, Sow PS, Mboup S, Kestens L, et al. Association between herpes simplex virus type 2 and HIV-1 in a population of married couples from Dakar, Senegal. International journal of STD & AIDS. 2012;23(11):810–4.
    OpenUrl
  194. 194.
    Odebisi-Omokanye M, Udeze A, Akanbi K, Jimoh N, Imam M. Serosurvey of Herpes Simplex Virus type-2 infection among HIV Infected Individuals Accessing a Secondary Health Care Facility in Kwara State, North Central Nigeria. Nig J Pure & Appl Sci. 2017;30(2).
  195. 195.
    Yunusa T, Haruna S, Garba H. Seroprevalence of Herpes Simplex virus among human immunodeficiency virus-positive patients in resource-limited setting. Journal of Global Infectious Diseases. 2019;11(3):107–11.
    OpenUrl
  196. 196.
    Aryee EA, Bailey RL, Natividad-Sancho A, Kaye S, Holland MJ. Detection, quantification and genotyping of Herpes Simplex Virus in cervicovaginal secretions by real-time PCR: a cross sectional survey. Virology journal. 2005;2(1):61.
    OpenUrl
  197. 197.
    Charpentier C, Koyalta D, Ndinaromtan M, Tchobkreo B, Jenabian MA, Day N, et al. Distribution of HIV-1 and HSV-2 epidemics in Chad revealing HSV-2 hot-spot in regions of high-risk HIV spread. Journal of infection in developing countries. 2011;5(1):64–7.
    OpenUrl
  198. 198.
    Eis-Hubinger AM, Nyankiye E, Bitoungui DM, Ndjomou J. Prevalence of herpes simplex virus type 2 antibody in Cameroon. Sexually Transmitted Diseases. 2002;29(11):637–42.
    OpenUrlPubMedWeb of Science
  199. 199.
    Ozouaki F, Ndjoyi-Mbiguino A, Legoff J, Onas IN, Kendjo E, Si-Mohamed A, et al. Genital shedding of herpes simplex virus type 2 in childbearing-aged and pregnant women living in Gabon. International journal of STD & AIDS. 2006;17(2):124–7.
    OpenUrl
  200. 200.
    Volpi A, Sarmati L, Suligoi B, Montano M, Rezza G, Andreoni M. Correlates of human herpes virus-8 and herpes simplex virus type 2 infections in Northern Cameroon. Journal of Medical Virology. 2004;74(3):467–72.
    OpenUrlPubMed
  201. 201.
    Longo JDD, Simaleko MM, Diemer HSC, Gresenguet G, Brucker G, Belec L. Risk factors for HIV infection among female sex workers in Bangui, Central African Republic. PLoS ONE. 2017;12(11):e0187654.
    OpenUrl
  202. 202.
    Nzila N, Laga M, Thiam MA, Mayimona K, Edidi B, Van Dyck E, et al. HIV and other sexually transmitted diseases among female prostitutes in Kinshasa. AIDS. 1991;5(6):715–21.
    OpenUrlPubMedWeb of Science
  203. 203.
    LeGoff J, Gresenguet G, Gody C, Longo JDD, Khonde N, Weiss HA, et al. Performance of the BioPlex 2200 multiplexing immunoassay platform for the detection of herpes simplex virus type 2 specific antibodies in African settings. Clinical and Vaccine Immunology. 2011;18(7):1191–3.
    OpenUrl
  204. 204.
    Mbopi-Keou FX, Gresenguet G, Mayaud P, Weiss HA, Gopal R, Matta M, et al. Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in african women: Opportunities for intervention. Journal of Infectious Diseases. 2000;182(4):1090–6.
    OpenUrlCrossRefPubMedWeb of Science
  205. 205.
    Vandepitte JM, Malele F, Kivuvu DM, Edidi S, Muwonga J, Lepira F, et al. HIV and other sexually transmitted infections among female sex workers in Kinshasa, Democratic Republic of Congo, in 2002. Sexually transmitted diseases. 2007;34(4):203–8.
    OpenUrlCrossRefPubMedWeb of Science
  206. 206.
    Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Lancet (London, England). 2019;394(10195):303–13.
    OpenUrl
  207. 207.
    Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine. 2015;372(6):509–18.
    OpenUrlCrossRefPubMed
  208. 208.
    Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infectious Diseases. 2012;12(1):19–26.
    OpenUrlCrossRefPubMedWeb of Science
  209. 209.
    LeGoff J, Weiss HA, Gresenguet G, Nzambi K, Frost E, Hayes RJ, et al. Cervicovaginal HIV-1 and herpes simplex virus type 2 shedding during genital ulcer disease episodes. Aids. 2007;21(12):1569–78.
    OpenUrlCrossRefPubMedWeb of Science
  210. 210.
    Ahmed HJ, Mbwana J, Gunnarsson E, Ahlman K, Guerino C, Svensson LA, et al. Etiology of genital ulcer disease and association with human immunodeficiency virus infection in two tanzanian cities. Sexually transmitted diseases. 2003;30(2):114–9.
    OpenUrlCrossRefPubMedWeb of Science
  211. 211.
    Gray RH, Serwadda D, Tobian AA, Chen MZ, Makumbi F, Suntoke T, et al. Effects of genital ulcer disease and herpes simplex virus type 2 on the efficacy of male circumcision for HIV prevention: Analyses from the Rakai trials. PLoS medicine. 2009;6(11):e1000187.
    OpenUrl
  212. 212.
    Kamya MR, Nsubuga P, Grant RM, Hellman N. The high prevalence of genital herpes among patients with genital ulcer disease in Uganda. Sexually transmitted diseases. 1995;22(6):351–4.
    OpenUrlPubMedWeb of Science
  213. 213.
    Makasa M, Buve A, Sandoy IF. Etiologic pattern of genital ulcers in Lusaka, Zambia: has chancroid been eliminated? Sexually transmitted diseases. 2012;39(10):787–91.
    OpenUrlCrossRefPubMed
  214. 214.
    Mayaud P, Nagot N, Konate I, Ouedraogo A, Weiss HA, Foulongne V, et al. Effect of HIV-1 and antiretroviral therapy on herpes simplex virus type 2: A prospective study in African women. Sexually Transmitted Infections. 2008;84(5):332–7.
    OpenUrlAbstract/FREE Full Text
  215. 215.
    Mungati M, Machiha A, Mugurungi O, Tshimanga M, Kilmarx PH, Nyakura J, et al. The Etiology of Genital Ulcer Disease and Coinfections With Chlamydia trachomatis and Neisseria gonorrhoeae in Zimbabwe: Results From the Zimbabwe STI Etiology Study. Sexually transmitted diseases. 2018;45(1):61–8.
    OpenUrl
  216. 216.
    Nilsen A, Kasubi MJ, Mohn SC, Mwakagile D, Langeland N, Haarr L. Herpes simplex virus infection and genital ulcer disease among patients with sexually transmitted infections in Dar es Salaam, Tanzania. Acta dermato-venereologica. 2007;87(4):355–9.
    OpenUrlCrossRefPubMedWeb of Science
  217. 217.
    Oni AA, Adu FD, Ekweozor CC, Bakare RA. Herpetic urethritis in male patients in Ibadan. West African journal of medicine. 1997;16(1):27–9.
    OpenUrlPubMed
  218. 218.
    Paz-Bailey G, Rahman M, Chen C, Ballard R, Moffat HJ, Kenyon T, et al. Changes in the etiology of sexually transmitted diseases in botswana between 1993 and 2002: Implications for the clinical management of genital ulcer disease. Clinical Infectious Diseases. 2005;41(9):1304–12.
    OpenUrlCrossRefPubMedWeb of Science
  219. 219.
    Pickering JM, Whitworth JA, Hughes P, Kasse M, Morgan D, Mayanja B, et al. Aetiology of sexually transmitted infections and response to syndromic treatment in southwest Uganda. Sexually transmitted infections. 2005;81(6):488–93.
    OpenUrlAbstract/FREE Full Text
  220. 220.
    Tanton C, Weiss HA, Rusizoka M, Legoff J, Changalucha J, Baisley K, et al. Long-term impact of acyclovir suppressive therapy on genital and plasma HIV RNA in Tanzanian women: a randomized controlled trial. The Journal of infectious diseases. 2010;201(9):1285–97.
    OpenUrlCrossRefPubMedWeb of Science
  221. 221.
    Lai W, Chen CY, Morse SA, Htun Y, Fehler HG, Liu H, et al. Increasing relative prevalence of HSV-2 infection among men with genital ulcers from a mining community in South Africa. Sexually transmitted infections. 2003;79(3):202–7.
    OpenUrlAbstract/FREE Full Text
Back to top
Posted January 26, 2021.
Download PDF
Data/Code
Email
The epidemiology of herpes simplex virus type 2 in sub-Saharan Africa: systematic review, meta-analyses, and meta-regressions
Manale Harfouche, Farah M. Abu-Hijleh, Charlotte James, Katharine J. Looker, Laith J. Abu-Raddad
medRxiv 2021.01.25.21250443; doi: https://doi.org/10.1101/2021.01.25.21250443
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area